{"data_date":"2026-11-08","library_size":29380,"matched_against":"each record's title and abstract (summary field), case-insensitive","n":351,"page":"https://alzhub.org/answers/aria-brain-swelling","query":"title or abstract mentions \"ARIA\", \"ARIA-E\", \"ARIA-H\" or \"amyloid-related imaging abnormalities\"","studies":[{"alzhub_score":15,"alzhub_url":"https://alzhub.org/study/fda-approves-leqembi-lecanemab-irmb-under-the-accelerated-approval-149a0541","doi":null,"journal":"U.S. Food and Drug Administration (announced via Biogen press release)","n_participants":null,"pmid":null,"source_url":"https://investors.biogen.com/news-releases/news-release-details/fda-approves-leqembitm-lecanemab-irmb-under-accelerated-approval","study_design":"regulatory decision","title":"FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease","title_match":false,"year":2023},{"alzhub_score":14,"alzhub_url":"https://alzhub.org/study/fda-converts-novel-alzheimer-s-disease-treatment-to-traditional-826d45e8","doi":null,"journal":"U.S. Food and Drug Administration","n_participants":null,"pmid":null,"source_url":"https://www.fda.gov/news-events/press-announcements/fda-converts-novel-alzheimers-disease-treatment-traditional-approval","study_design":"regulatory decision","title":"FDA Converts Novel Alzheimer's Disease Treatment to Traditional Approval","title_match":false,"year":2023},{"alzhub_score":15,"alzhub_url":"https://alzhub.org/study/fda-approves-treatment-for-adults-with-alzheimer-s-disease-kisunla-7f8e71c0","doi":null,"journal":"U.S. Food and Drug Administration","n_participants":null,"pmid":null,"source_url":"https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-adults-alzheimers-disease","study_design":"regulatory decision","title":"FDA Approves Treatment for Adults with Alzheimer's Disease (Kisunla / donanemab-azbt)","title_match":false,"year":2024},{"alzhub_score":74,"alzhub_url":"https://alzhub.org/study/lecanemab-in-early-alzheimer-s-disease-22dd8fce","doi":null,"journal":"New England Journal of Medicine","n_participants":1795,"pmid":null,"source_url":"https://pubmed.ncbi.nlm.nih.gov/36449413/","study_design":"phase-3-trial","title":"Lecanemab in Early Alzheimer's Disease","title_match":false,"year":2023},{"alzhub_score":74,"alzhub_url":"https://alzhub.org/study/donanemab-in-early-symptomatic-alzheimer-disease-the-trailblazer-alz-9857475c","doi":null,"journal":"JAMA","n_participants":1736,"pmid":null,"source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10352931/","study_design":"phase-3-trial","title":"Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial","title_match":false,"year":2023},{"alzhub_score":15,"alzhub_url":"https://alzhub.org/study/leqembi-recommended-for-treatment-of-early-alzheimer-s-disease-chmp-6280b4fa","doi":null,"journal":"European Medicines Agency","n_participants":null,"pmid":null,"source_url":"https://www.ema.europa.eu/en/news/leqembi-recommended-treatment-early-alzheimers-disease","study_design":"regulatory decision","title":"Leqembi Recommended for Treatment of Early Alzheimer's Disease (CHMP re-examination, reversing July 2024 refusal)","title_match":false,"year":2024},{"alzhub_score":15,"alzhub_url":"https://alzhub.org/study/kisunla-donanemab-eu-marketing-authorization-epar-following-chmp-re-87b2f0ae","doi":null,"journal":"European Medicines Agency","n_participants":null,"pmid":null,"source_url":"https://www.ema.europa.eu/en/medicines/human/EPAR/kisunla","study_design":"regulatory decision","title":"Kisunla (donanemab) \u2014 EU Marketing Authorization (EPAR), following CHMP re-examination","title_match":false,"year":2025},{"alzhub_score":69,"alzhub_url":"https://alzhub.org/study/amyloid-related-imaging-abnormalities-aria-in-anti-amyloid-therapies-912127c4","doi":null,"journal":"Alzheimer's & Dementia","n_participants":null,"pmid":null,"source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13099593/","study_design":"systematic-review","title":"Amyloid-Related Imaging Abnormalities (ARIA) in Anti-Amyloid Therapies for Alzheimer's Disease: An Update from the Alzheimer's Association ARIA Workgroup","title_match":true,"year":2026},{"alzhub_score":16,"alzhub_url":"https://alzhub.org/study/interim-phase-1-multiple-ascending-dose-results-for-remternetug-955fa2a8","doi":null,"journal":"Presented at AD/PD 2023 Conference (Gothenburg, Sweden); covered by ALZFORUM and NeurologyLive","n_participants":41,"pmid":null,"source_url":"https://www.alzforum.org/therapeutics/remternetug","study_design":"RCT","title":"Interim Phase 1 multiple ascending dose results for remternetug (LY3372993) in Alzheimer's disease","title_match":false,"year":2023},{"alzhub_score":83,"alzhub_url":"https://alzhub.org/study/amyloid-related-imaging-abnormalities-with-donanemab-in-early-40063015","doi":"10.1001/jamaneurol.2025.0065","journal":"JAMA Neurology","n_participants":3030,"pmid":"40063015","source_url":"https://pubmed.ncbi.nlm.nih.gov/40063015/","study_design":"phase-3-trial","title":"Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical Trials","title_match":true,"year":2025},{"alzhub_score":76,"alzhub_url":"https://alzhub.org/study/modified-titration-of-donanemab-reduces-aria-risk-and-maintains-40172303","doi":"10.1002/alz.70062","journal":"Alzheimer's & Dementia","n_participants":843,"pmid":"40172303","source_url":"https://pubmed.ncbi.nlm.nih.gov/40172303/","study_design":"phase-3-trial","title":"Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction","title_match":true,"year":2025},{"alzhub_score":63,"alzhub_url":"https://alzhub.org/study/long-term-safety-and-efficacy-of-lecanemab-in-early-alzheimer-s-41355080","doi":"10.1002/alz.70905","journal":"Alzheimer's & Dementia","n_participants":null,"pmid":"41355080","source_url":"https://pubmed.ncbi.nlm.nih.gov/41355080/","study_design":"phase-3-trial","title":"Long-term safety and efficacy of lecanemab in early Alzheimer's disease: Results from the Clarity AD open-label extension study","title_match":false,"year":2025},{"alzhub_score":71,"alzhub_url":"https://alzhub.org/study/lecanemab-treatment-in-a-specialty-memory-clinic-40354064","doi":"10.1001/jamaneurol.2025.1232","journal":"JAMA Neurology","n_participants":234,"pmid":"40354064","source_url":"https://pubmed.ncbi.nlm.nih.gov/40354064/","study_design":"cohort","title":"Lecanemab Treatment in a Specialty Memory Clinic","title_match":false,"year":2025},{"alzhub_score":53,"alzhub_url":"https://alzhub.org/study/clonal-expansion-of-cytotoxic-cd8-t-cells-in-lecanemab-associated-aria-41617706","doi":"10.1038/s41467-026-68921-3","journal":"Nature Communications","n_participants":3,"pmid":"41617706","source_url":"https://pubmed.ncbi.nlm.nih.gov/41617706/","study_design":"case-control","title":"Clonal expansion of cytotoxic CD8\u207a T cells in lecanemab-associated ARIA","title_match":true,"year":2026},{"alzhub_score":76,"alzhub_url":"https://alzhub.org/study/amyloid-beta-targeting-monoclonal-antibodies-for-people-with-mild-41985900","doi":"10.1002/14651858.CD016297","journal":"Cochrane Database of Systematic Reviews","n_participants":20342,"pmid":"41985900","source_url":"https://pubmed.ncbi.nlm.nih.gov/41985900/","study_design":"meta-analysis","title":"Amyloid-beta-targeting monoclonal antibodies for people with mild cognitive impairment or mild dementia due to Alzheimer's disease (Cochrane review)","title_match":false,"year":2026},{"alzhub_score":74,"alzhub_url":"https://alzhub.org/study/clinically-important-benefits-and-harms-of-monoclonal-antibodies-38253509","doi":"10.1370/afm.3050","journal":"Annals of Family Medicine","n_participants":23202,"pmid":"38253509","source_url":"https://pubmed.ncbi.nlm.nih.gov/38253509/","study_design":"meta-analysis","title":"Clinically Important Benefits and Harms of Monoclonal Antibodies Targeting Amyloid for the Treatment of Alzheimer Disease: A Systematic Review and Meta-Analysis","title_match":false,"year":2024},{"alzhub_score":73,"alzhub_url":"https://alzhub.org/study/the-trem2-agonistic-antibody-al002-in-early-alzheimer-s-disease-a-41787076","doi":"10.1038/s41591-026-04273-1","journal":"Nature Medicine","n_participants":381,"pmid":"41787076","source_url":"https://pubmed.ncbi.nlm.nih.gov/41787076/","study_design":"phase-2-trial","title":"The TREM2 agonistic antibody AL002 in early Alzheimer's disease: a phase 2 randomized trial","title_match":false,"year":2026},{"alzhub_score":57,"alzhub_url":"https://alzhub.org/study/alzheimer-disease-neuropathology-in-a-patient-previously-treated-with-35581440","doi":"10.1007/s00401-022-02433-4","journal":"Acta neuropathologica","n_participants":null,"pmid":"35581440","source_url":"https://pubmed.ncbi.nlm.nih.gov/35581440/","study_design":"case report","title":"Alzheimer disease neuropathology in a patient previously treated with aducanumab","title_match":false,"year":2022},{"alzhub_score":65,"alzhub_url":"https://alzhub.org/study/amyloid-related-imaging-abnormalities-in-the-dian-tu-001-trial-of-36151869","doi":"10.1002/ana.26511","journal":"Annals of neurology","n_participants":52,"pmid":"36151869","source_url":"https://pubmed.ncbi.nlm.nih.gov/36151869/","study_design":"cross-sectional","title":"Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease","title_match":true,"year":2022},{"alzhub_score":68,"alzhub_url":"https://alzhub.org/study/biomarker-pattern-of-aria-e-participants-in-phase-3-randomized-29429971","doi":"10.1212/wnl.0000000000005060","journal":"Neurology","n_participants":1512,"pmid":"29429971","source_url":"https://pubmed.ncbi.nlm.nih.gov/29429971/","study_design":"longitudinal study","title":"Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab","title_match":true,"year":2018},{"alzhub_score":44,"alzhub_url":"https://alzhub.org/study/amyloid-pet-a-questionable-single-primary-surrogate-efficacy-measure-36278356","doi":"10.3233/jad-220841","journal":"Journal of Alzheimer's disease : JAD","n_participants":null,"pmid":"36278356","source_url":"https://pubmed.ncbi.nlm.nih.gov/36278356/","study_design":null,"title":"Amyloid PET: A Questionable Single Primary Surrogate Efficacy Measure on Alzheimer Immunotherapy Trials","title_match":false,"year":2022},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/fdg-pet-and-mri-for-monitoring-immunotherapy-in-alzheimer-disease-37314733","doi":"10.1097/rlu.0000000000004710","journal":"Clinical nuclear medicine","n_participants":null,"pmid":"37314733","source_url":"https://pubmed.ncbi.nlm.nih.gov/37314733/","study_design":null,"title":"FDG PET (and MRI) for Monitoring Immunotherapy in Alzheimer Disease","title_match":false,"year":2023},{"alzhub_score":85,"alzhub_url":"https://alzhub.org/study/two-phase-3-trials-of-bapineuzumab-in-mild-to-moderate-alzheimer-s-24450891","doi":"10.1056/nejmoa1304839","journal":"The New England journal of medicine","n_participants":1090,"pmid":"24450891","source_url":"https://pubmed.ncbi.nlm.nih.gov/24450891/","study_design":"clinical trial","title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease","title_match":false,"year":2014},{"alzhub_score":62,"alzhub_url":"https://alzhub.org/study/amyloid-related-imaging-abnormalities-in-patients-with-alzheimer-s-22305802","doi":"10.1016/s1474-4422(12)70015-7","journal":"The Lancet. Neurology","n_participants":262,"pmid":"22305802","source_url":"https://pubmed.ncbi.nlm.nih.gov/22305802/","study_design":"clinical trial","title":"Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis","title_match":true,"year":2012},{"alzhub_score":72,"alzhub_url":"https://alzhub.org/study/amyloid-related-imaging-abnormalities-and-amyloid-targeting-35099507","doi":"10.1001/jamaneurol.2021.5205","journal":"JAMA neurology","n_participants":null,"pmid":"35099507","source_url":"https://pubmed.ncbi.nlm.nih.gov/35099507/","study_design":"systematic review","title":"Amyloid-Related Imaging Abnormalities and \u03b2-Amyloid-Targeting Antibodies: A Systematic Review","title_match":true,"year":2022},{"alzhub_score":67,"alzhub_url":"https://alzhub.org/study/spontaneous-aria-like-events-in-cerebral-amyloid-angiopathy-related-34531298","doi":"10.1212/wnl.0000000000012778","journal":"Neurology","n_participants":113,"pmid":"34531298","source_url":"https://pubmed.ncbi.nlm.nih.gov/34531298/","study_design":"longitudinal study","title":"Spontaneous ARIA-like Events in Cerebral Amyloid Angiopathy-Related Inflammation: A Multicenter Prospective Longitudinal Cohort Study","title_match":true,"year":2021},{"alzhub_score":83,"alzhub_url":"https://alzhub.org/study/amyloid-related-imaging-abnormalities-in-2-phase-3-studies-evaluating-34807243","doi":"10.1001/jamaneurol.2021.4161","journal":"JAMA neurology","n_participants":1087,"pmid":"34807243","source_url":"https://pubmed.ncbi.nlm.nih.gov/34807243/","study_design":"clinical trial","title":"Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease","title_match":true,"year":2022},{"alzhub_score":74,"alzhub_url":"https://alzhub.org/study/abby-a-phase-2-randomized-trial-of-crenezumab-in-mild-to-moderate-29695589","doi":"10.1212/wnl.0000000000005550","journal":"Neurology","n_participants":184,"pmid":"29695589","source_url":"https://pubmed.ncbi.nlm.nih.gov/29695589/","study_design":"clinical trial","title":"ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease","title_match":false,"year":2018},{"alzhub_score":81,"alzhub_url":"https://alzhub.org/study/evaluating-the-safety-and-efficacy-of-crenezumab-vs-placebo-in-adults-36121669","doi":"10.1001/jamaneurol.2022.2909","journal":"JAMA neurology","n_participants":3664,"pmid":"36121669","source_url":"https://pubmed.ncbi.nlm.nih.gov/36121669/","study_design":"clinical trial","title":"Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled Trials","title_match":false,"year":2022},{"alzhub_score":78,"alzhub_url":"https://alzhub.org/study/accelerated-brain-volume-loss-caused-by-anti-amyloid-drugs-a-36973044","doi":"10.1212/wnl.0000000000207156","journal":"Neurology","n_participants":8062,"pmid":"36973044","source_url":"https://pubmed.ncbi.nlm.nih.gov/36973044/","study_design":"systematic review","title":"Accelerated Brain Volume Loss Caused by Anti-\u03b2-Amyloid Drugs: A Systematic Review and Meta-analysis","title_match":false,"year":2023},{"alzhub_score":77,"alzhub_url":"https://alzhub.org/study/amyloid-related-imaging-abnormalities-aria-in-clinical-trials-of-39556389","doi":"10.1001/jamaneurol.2024.3937","journal":"JAMA neurology","n_participants":985,"pmid":"39556389","source_url":"https://pubmed.ncbi.nlm.nih.gov/39556389/","study_design":"clinical trial","title":"Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease","title_match":true,"year":2025},{"alzhub_score":61,"alzhub_url":"https://alzhub.org/study/a-phase-ii-randomized-double-blind-placebo-controlled-study-of-safety-27589523","doi":"10.3233/jad-160369","journal":"Journal of Alzheimer's disease : JAD","n_participants":146,"pmid":"27589523","source_url":"https://pubmed.ncbi.nlm.nih.gov/27589523/","study_design":null,"title":"A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Safety, Pharmacokinetics, and Biomarker Results of Subcutaneous Bapineuzumab in Patients with mild to moderate Alzheimer's disease","title_match":false,"year":2016},{"alzhub_score":71,"alzhub_url":"https://alzhub.org/study/incidence-of-amyloid-related-imaging-abnormalities-in-phase-iii-40112274","doi":"10.1212/wnl.0000000000213483","journal":"Neurology","n_participants":6315,"pmid":"40112274","source_url":"https://pubmed.ncbi.nlm.nih.gov/40112274/","study_design":"meta-analysis","title":"Incidence of Amyloid-Related Imaging Abnormalities in Phase III Clinical Trials of Anti-Amyloid-\u03b2 Immunotherapy: An Updated Meta-Analysis","title_match":true,"year":2025},{"alzhub_score":57,"alzhub_url":"https://alzhub.org/study/lecanemab-questions-38484213","doi":"10.1212/wnl.0000000000209320","journal":"Neurology","n_participants":null,"pmid":"38484213","source_url":"https://pubmed.ncbi.nlm.nih.gov/38484213/","study_design":"randomized controlled trial","title":"Lecanemab Questions","title_match":false,"year":2024},{"alzhub_score":50,"alzhub_url":"https://alzhub.org/study/amyloid-related-imaging-abnormalities-with-anti-amyloid-antibodies-35401412","doi":"10.3389/fneur.2022.862369","journal":"Frontiers in neurology","n_participants":null,"pmid":"35401412","source_url":"https://pubmed.ncbi.nlm.nih.gov/35401412/","study_design":null,"title":"Amyloid-Related Imaging Abnormalities With Anti-amyloid Antibodies for the Treatment of Dementia Due to Alzheimer's Disease","title_match":true,"year":2022},{"alzhub_score":46,"alzhub_url":"https://alzhub.org/study/cerebral-amyloid-angiopathy-emerging-concepts-25692104","doi":"10.5853/jos.2015.17.1.17","journal":"Journal of stroke","n_participants":null,"pmid":"25692104","source_url":"https://pubmed.ncbi.nlm.nih.gov/25692104/","study_design":null,"title":"Cerebral amyloid angiopathy: emerging concepts","title_match":false,"year":2015},{"alzhub_score":48,"alzhub_url":"https://alzhub.org/study/amyloid-related-imaging-abnormalities-an-update-36321981","doi":"10.2214/ajr.22.28461","journal":"AJR. American journal of roentgenology","n_participants":null,"pmid":"36321981","source_url":"https://pubmed.ncbi.nlm.nih.gov/36321981/","study_design":null,"title":"Amyloid-Related Imaging Abnormalities: An Update","title_match":true,"year":2023},{"alzhub_score":47,"alzhub_url":"https://alzhub.org/study/amyloid-related-imaging-abnormalities-in-alzheimer-disease-treated-37651273","doi":"10.1148/rg.230009","journal":"Radiographics : a review publication of the Radiological Society of North America, Inc","n_participants":null,"pmid":"37651273","source_url":"https://pubmed.ncbi.nlm.nih.gov/37651273/","study_design":null,"title":"Amyloid-related Imaging Abnormalities in Alzheimer Disease Treated with Anti-Amyloid-\u03b2 Therapy","title_match":true,"year":2023},{"alzhub_score":60,"alzhub_url":"https://alzhub.org/study/association-of-microglial-activation-with-spontaneous-aria-e-and-csf-35940900","doi":"10.1212/wnl.0000000000200892","journal":"Neurology","n_participants":null,"pmid":"35940900","source_url":"https://pubmed.ncbi.nlm.nih.gov/35940900/","study_design":"longitudinal study","title":"Association of Microglial Activation With Spontaneous ARIA-E and CSF Levels of Anti-A\u03b2 Autoantibodies","title_match":true,"year":2022},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/immunotherapy-for-alzheimer-s-disease-24412277","doi":"10.1016/j.bcp.2013.12.020","journal":"Biochemical pharmacology","n_participants":null,"pmid":"24412277","source_url":"https://pubmed.ncbi.nlm.nih.gov/24412277/","study_design":null,"title":"Immunotherapy for Alzheimer's disease","title_match":false,"year":2014},{"alzhub_score":81,"alzhub_url":"https://alzhub.org/study/a-randomized-double-blind-phase-2b-proof-of-concept-clinical-trial-in-33865446","doi":"10.1186/s13195-021-00813-8","journal":"Alzheimer's research & therapy","n_participants":18,"pmid":"33865446","source_url":"https://pubmed.ncbi.nlm.nih.gov/33865446/","study_design":"clinical trial","title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-A\u03b2 protofibril antibody","title_match":false,"year":2021},{"alzhub_score":78,"alzhub_url":"https://alzhub.org/study/a-phase-iii-randomized-trial-of-gantenerumab-in-prodromal-alzheimer-s-29221491","doi":"10.1186/s13195-017-0318-y","journal":"Alzheimer's research & therapy","n_participants":3089,"pmid":"29221491","source_url":"https://pubmed.ncbi.nlm.nih.gov/29221491/","study_design":null,"title":"A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease","title_match":false,"year":2017},{"alzhub_score":69,"alzhub_url":"https://alzhub.org/study/core-csf-biomarker-profile-in-cerebral-amyloid-angiopathy-updated-39270153","doi":"10.1212/wnl.0000000000209795","journal":"Neurology","n_participants":289,"pmid":"39270153","source_url":"https://pubmed.ncbi.nlm.nih.gov/39270153/","study_design":"meta-analysis","title":"Core CSF Biomarker Profile in Cerebral Amyloid Angiopathy: Updated Meta-Analysis","title_match":false,"year":2024},{"alzhub_score":46,"alzhub_url":"https://alzhub.org/study/lecanemab-in-symptomatic-psen1-p-met233val-early-onset-alzheimer-s-42676462","doi":"10.1002/dad2.70468","journal":"Alzheimer's & dementia (Amsterdam, Netherlands)","n_participants":null,"pmid":"42676462","source_url":"https://pubmed.ncbi.nlm.nih.gov/42676462/","study_design":"longitudinal study","title":"Lecanemab in symptomatic PSEN1 p.Met233Val early-onset Alzheimer's disease: Neuroimaging safety, regional amyloid-PET dynamics, and longitudinal plasma biomarkers","title_match":false,"year":2026},{"alzhub_score":48,"alzhub_url":"https://alzhub.org/study/vessels-sing-their-arias-the-role-of-vascular-amyloid-in-the-age-of-34905943","doi":"10.1161/strokeaha.121.036873","journal":"Stroke","n_participants":null,"pmid":"34905943","source_url":"https://pubmed.ncbi.nlm.nih.gov/34905943/","study_design":null,"title":"Vessels Sing Their ARIAs: The Role of Vascular Amyloid in the Age of Aducanumab","title_match":false,"year":2022},{"alzhub_score":59,"alzhub_url":"https://alzhub.org/study/genome-wide-association-studies-of-aria-from-the-aducanumab-phase-3-38165296","doi":"10.1212/wnl.0000000000207919","journal":"Neurology","n_participants":1691,"pmid":"38165296","source_url":"https://pubmed.ncbi.nlm.nih.gov/38165296/","study_design":"clinical trial","title":"Genome-Wide Association Studies of ARIA From the Aducanumab Phase 3 ENGAGE and EMERGE Studies","title_match":true,"year":2024},{"alzhub_score":69,"alzhub_url":"https://alzhub.org/study/incidence-of-amyloid-related-imaging-abnormalities-in-patients-with-36038268","doi":"10.1212/wnl.0000000000201019","journal":"Neurology","n_participants":9429,"pmid":"36038268","source_url":"https://pubmed.ncbi.nlm.nih.gov/36038268/","study_design":"clinical trial","title":"Incidence of Amyloid-Related Imaging Abnormalities in Patients With Alzheimer Disease Treated With Anti-\u03b2-Amyloid Immunotherapy: A Meta-analysis","title_match":true,"year":2022},{"alzhub_score":53,"alzhub_url":"https://alzhub.org/study/artificial-intelligence-assistive-software-tool-for-automated-38345816","doi":"10.1001/jamanetworkopen.2023.55800","journal":"JAMA network open","n_participants":16,"pmid":"38345816","source_url":"https://pubmed.ncbi.nlm.nih.gov/38345816/","study_design":null,"title":"Artificial Intelligence Assistive Software Tool for Automated Detection and Quantification of Amyloid-Related Imaging Abnormalities","title_match":true,"year":2024},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/therapeutic-anti-amyloid-antibodies-cause-neuronal-disturbances-36515320","doi":"10.1002/alz.12833","journal":"Alzheimer's & dementia : the journal of the Alzheimer's Association","n_participants":null,"pmid":"36515320","source_url":"https://pubmed.ncbi.nlm.nih.gov/36515320/","study_design":null,"title":"Therapeutic anti-amyloid \u03b2 antibodies cause neuronal disturbances","title_match":false,"year":2023},{"alzhub_score":67,"alzhub_url":"https://alzhub.org/study/neuropathological-changes-and-amyloid-related-imaging-abnormalities-41109234","doi":"10.1016/s1474-4422(25)00313-8","journal":"The Lancet. Neurology","n_participants":null,"pmid":"41109234","source_url":"https://pubmed.ncbi.nlm.nih.gov/41109234/","study_design":"case-control study","title":"Neuropathological changes and amyloid-related imaging abnormalities in Alzheimer's disease treated with aducanumab versus untreated: a retrospective case-control study","title_match":true,"year":2025},{"alzhub_score":56,"alzhub_url":"https://alzhub.org/study/refractory-status-epilepticus-in-a-patient-with-aducanumab-induced-39121445","doi":"10.1212/wnl.0000000000209582","journal":"Neurology","n_participants":null,"pmid":"39121445","source_url":"https://pubmed.ncbi.nlm.nih.gov/39121445/","study_design":"longitudinal study","title":"Refractory Status Epilepticus in a Patient With Aducanumab-Induced Amyloid-Related Imaging Abnormalities","title_match":true,"year":2024},{"alzhub_score":33,"alzhub_url":"https://alzhub.org/study/commentary-aducanumab-related-aria-paean-or-lament-35543641","doi":"10.1097/rlu.0000000000004252","journal":"Clinical nuclear medicine","n_participants":null,"pmid":"35543641","source_url":"https://pubmed.ncbi.nlm.nih.gov/35543641/","study_design":null,"title":"Commentary: Aducanumab-Related ARIA: Paean or Lament?","title_match":true,"year":2022},{"alzhub_score":35,"alzhub_url":"https://alzhub.org/study/aducanumab-related-amyloid-related-imaging-abnormalities-paean-or-35452007","doi":"10.1097/rlu.0000000000004250","journal":"Clinical nuclear medicine","n_participants":null,"pmid":"35452007","source_url":"https://pubmed.ncbi.nlm.nih.gov/35452007/","study_design":null,"title":"Aducanumab-Related Amyloid-Related Imaging Abnormalities: Paean or Lament?","title_match":true,"year":2022},{"alzhub_score":32,"alzhub_url":"https://alzhub.org/study/re-aducanumab-related-aria-paean-or-lament-36607365","doi":"10.1097/rlu.0000000000004490","journal":"Clinical nuclear medicine","n_participants":null,"pmid":"36607365","source_url":"https://pubmed.ncbi.nlm.nih.gov/36607365/","study_design":null,"title":"Re: Aducanumab-Related ARIA: Paean or Lament?","title_match":true,"year":2023},{"alzhub_score":35,"alzhub_url":"https://alzhub.org/study/a-time-to-event-exposure-response-model-for-amyloid-related-imaging-35285968","doi":"10.1002/jcph.2047","journal":"Journal of clinical pharmacology","n_participants":3251,"pmid":"35285968","source_url":"https://pubmed.ncbi.nlm.nih.gov/35285968/","study_design":"clinical trial","title":"A Time-to-Event Exposure-Response Model for Amyloid-Related Imaging Abnormalities Following Administration of Aducanumab to Subjects With Early Alzheimer Disease","title_match":true,"year":2022},{"alzhub_score":39,"alzhub_url":"https://alzhub.org/study/incidence-of-amyloid-related-imaging-abnormalities-and-health-41885326","doi":"10.18553/jmcp.2026.32.4.470","journal":"Journal of managed care & specialty pharmacy","n_participants":240,"pmid":"41885326","source_url":"https://pubmed.ncbi.nlm.nih.gov/41885326/","study_design":null,"title":"Incidence of amyloid-related imaging abnormalities and health resource utilization in patients with Alzheimer disease receiving monoclonal antibody treatments: A real-world evidence study","title_match":true,"year":2026},{"alzhub_score":16,"alzhub_url":"https://alzhub.org/study/anti-amyloid-antibody-equilibrium-binding-to-a-aggregates-from-human-35ab99e8","doi":"10.1101/2025.05.20.654902","journal":"bioRxiv","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.1101/2025.05.20.654902","study_design":"cross-sectional","title":"Anti-amyloid antibody equilibrium binding to A\u03b2 aggregates from human Alzheimer disease brain","title_match":false,"year":2025},{"alzhub_score":38,"alzhub_url":"https://alzhub.org/study/amyloid-pet-signal-reduction-in-prior-aria-e-regions-after-41260674","doi":"10.3174/ajnr.a9111","journal":"American Journal of Neuroradiology","n_participants":null,"pmid":"41260674","source_url":"https://pubmed.ncbi.nlm.nih.gov/41260674/","study_design":null,"title":"\u03b2-Amyloid PET Signal Reduction in Prior ARIA-E Regions after Antiamyloid Therapy for Alzheimer Disease","title_match":true,"year":2025},{"alzhub_score":32,"alzhub_url":"https://alzhub.org/study/amyloid-pet-signal-reduction-in-regions-with-aria-e-following-anti-cc666680","doi":"10.1212/wnl.0000000000215645","journal":"Neurology","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.1212/wnl.0000000000215645","study_design":null,"title":"\u03b2-amyloid PET Signal Reduction in Regions with ARIA-E Following Anti-amyloid Therapy for Alzheimer Disease (P1-12.010)","title_match":true,"year":2026},{"alzhub_score":47,"alzhub_url":"https://alzhub.org/study/anti-amyloid-monoclonal-antibodies-in-early-alzheimer-disease-42784125","doi":"10.3390/neurolint18090171","journal":"Neurology International","n_participants":null,"pmid":"42784125","source_url":"https://pubmed.ncbi.nlm.nih.gov/42784125/","study_design":"meta-analysis","title":"Anti-Amyloid Monoclonal Antibodies in Early Alzheimer Disease: Lecanemab and Donanemab","title_match":false,"year":2026},{"alzhub_score":28,"alzhub_url":"https://alzhub.org/study/anticuerpos-monoclonales-antiamiloide-y-enfermedad-de-alzheimer-d85edb6b","doi":"10.24875/kranion.m26000124","journal":"Kranion","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.24875/kranion.m26000124","study_design":null,"title":"Anticuerpos monoclonales antiamiloide y enfermedad de Alzheimer: \u00bfestamos preparados?","title_match":false,"year":2026},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/lecanemab-aducanumab-and-donanemab-bind-the-same-human-alzheimer-41435407","doi":"10.1002/alz70855_099914","journal":"Alzheimer s & Dementia","n_participants":null,"pmid":"41435407","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12726945/","study_design":null,"title":"Lecanemab, aducanumab, and donanemab bind the same human Alzheimer disease A\u03b2 aggregates at different epitopes","title_match":false,"year":2025},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/pet-guided-assessment-of-amyloid-clearance-and-outcomes-in-a-real-42055956","doi":"10.3174/ajnr.a9387","journal":"American Journal of Neuroradiology","n_participants":15,"pmid":"42055956","source_url":"https://pubmed.ncbi.nlm.nih.gov/42055956/","study_design":"longitudinal study","title":"PET-guided Assessment of Amyloid Clearance and Outcomes in a Real-World Cohort of Patients with Alzheimer Disease undergoing Anti-Amyloid Therapy","title_match":false,"year":2026},{"alzhub_score":47,"alzhub_url":"https://alzhub.org/study/use-of-lecanemab-and-donanemab-in-the-canadian-healthcare-system-39893139","doi":"10.1016/j.tjpad.2025.100068","journal":"The Journal of Prevention of Alzheimer s Disease","n_participants":null,"pmid":"39893139","source_url":"https://pubmed.ncbi.nlm.nih.gov/39893139/","study_design":null,"title":"Use of lecanemab and donanemab in the Canadian healthcare system: Evidence, challenges, and areas for future research","title_match":false,"year":2025},{"alzhub_score":35,"alzhub_url":"https://alzhub.org/study/changes-of-a-cerebral-cavernous-malformation-associated-with-40584633","doi":"10.1212/cpj.0000000000200508","journal":"Neurology Clinical Practice","n_participants":null,"pmid":"40584633","source_url":"https://pubmed.ncbi.nlm.nih.gov/40584633/","study_design":null,"title":"Changes of a Cerebral Cavernous Malformation Associated With Lecanemab Therapy in a Patient With Alzheimer Disease","title_match":false,"year":2025},{"alzhub_score":56,"alzhub_url":"https://alzhub.org/study/are-deep-white-matter-hyperintensities-associated-with-amyloid-41038644","doi":"10.3174/ajnr.a8822","journal":"American Journal of Neuroradiology","n_participants":27,"pmid":"41038644","source_url":"https://pubmed.ncbi.nlm.nih.gov/41038644/","study_design":"cohort study","title":"Are Deep White Matter Hyperintensities Associated with Amyloid-Related Imaging Abnormalities in Patients with Alzheimer Disease Treated with Lecanemab?","title_match":true,"year":2025},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/clinical-practice-outcomes-with-lecanemab-for-alzheimer-disease-42746606","doi":"10.1212/wn9.0000000000000121","journal":"Neurology Open Access","n_participants":null,"pmid":"42746606","source_url":"https://pubmed.ncbi.nlm.nih.gov/42746606/","study_design":null,"title":"Clinical Practice Outcomes With Lecanemab for Alzheimer Disease","title_match":false,"year":2026},{"alzhub_score":39,"alzhub_url":"https://alzhub.org/study/a-new-era-in-neuropharmacology-assessing-the-efficacy-and-safety-of-42084750","doi":"10.1007/s00415-026-13829-7","journal":"Journal of Neurology","n_participants":null,"pmid":"42084750","source_url":"https://pubmed.ncbi.nlm.nih.gov/42084750/","study_design":null,"title":"A new era in neuropharmacology: assessing the efficacy and safety of novel anti-amyloid and non-amyloid drug targets for Alzheimer's disease","title_match":false,"year":2026},{"alzhub_score":49,"alzhub_url":"https://alzhub.org/study/safety-of-lecanemab-after-6month-treatment-in-the-diantu001-trial-41447712","doi":"10.1002/alz70859_105304","journal":"Alzheimer s & Dementia","n_participants":97,"pmid":"41447712","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12740332/","study_design":null,"title":"Safety of Lecanemab After 6\u2010Month Treatment in the DIAN\u2010TU\u2010001 Trial","title_match":false,"year":2025},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/lecanemab-binds-to-transgenic-mouse-modelderived-amyloid-fibril-40495448","doi":"10.1111/nan.70022","journal":"Neuropathology and Applied Neurobiology","n_participants":null,"pmid":"40495448","source_url":"https://pubmed.ncbi.nlm.nih.gov/40495448/","study_design":null,"title":"Lecanemab Binds to Transgenic Mouse Model\u2010Derived Amyloid\u2010\u03b2 Fibril Structures Resembling Alzheimer's Disease Type I, Type II and Arctic Folds","title_match":false,"year":2025},{"alzhub_score":38,"alzhub_url":"https://alzhub.org/study/real-world-safety-profile-of-lecanemab-a-disproportionality-analysis-cbaaba6e","doi":"10.1016/j.japhar.2025.100015","journal":"JAPhA Pharmacotherapy","n_participants":1307937,"pmid":null,"source_url":"https://doi.org/10.1016/j.japhar.2025.100015","study_design":null,"title":"Real-world safety profile of lecanemab: A disproportionality analysis of adverse events in the FDA adverse event reporting system","title_match":false,"year":2025},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/anti-amyloid-monoclonal-antibodies-and-amyloid-related-imaging-4ee39e2d","doi":"10.5281/zenodo.22310606","journal":"Zenodo (CERN European Organization for Nuclear Research)","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.5281/zenodo.22310606","study_design":"narrative review","title":"Anti-Amyloid Monoclonal Antibodies and Amyloid-Related Imaging Abnormalities in Early Alzheimer Disease","title_match":true,"year":2026},{"alzhub_score":50,"alzhub_url":"https://alzhub.org/study/anti-amyloid-monoclonal-antibodies-and-amyloid-related-imaging-95d6b60f","doi":"10.5281/zenodo.22310607","journal":"Zenodo (CERN European Organization for Nuclear Research)","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.5281/zenodo.22310607","study_design":"narrative review","title":"Anti-Amyloid Monoclonal Antibodies and Amyloid-Related Imaging Abnormalities in Early Alzheimer Disease","title_match":true,"year":2026},{"alzhub_score":31,"alzhub_url":"https://alzhub.org/study/lecanemab-donanemab-and-emerging-disease-modifying-therapies-for-d453d052","doi":"10.5281/zenodo.17615265","journal":"International Journal of Science and Research Archive","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.5281/zenodo.17615265","study_design":"narrative review","title":"Lecanemab, Donanemab, and Emerging Disease Modifying Therapies for Alzheimer Disease: Clinical Evidence and Primary Care Implications in Canada","title_match":false,"year":2025},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/lecanemab-donanemab-and-emerging-disease-modifying-therapies-for-08ace6f7","doi":"10.5281/zenodo.17615266","journal":"International Journal of Science and Research Archive","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.5281/zenodo.17615266","study_design":"narrative review","title":"Lecanemab, Donanemab, and Emerging Disease Modifying Therapies for Alzheimer Disease: Clinical Evidence and Primary Care Implications in Canada","title_match":false,"year":2025},{"alzhub_score":31,"alzhub_url":"https://alzhub.org/study/lecanemab-donanemab-and-emerging-disease-modifying-therapies-for-1b2f6657","doi":"10.30574/ijsra.2025.17.1.2929","journal":"International Journal of Science and Research Archive","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.30574/ijsra.2025.17.1.2929","study_design":"narrative review","title":"Lecanemab, Donanemab, and Emerging Disease Modifying Therapies for Alzheimer Disease: Clinical Evidence and Primary Care Implications in Canada","title_match":false,"year":2025},{"alzhub_score":44,"alzhub_url":"https://alzhub.org/study/monoclonal-antibodies-for-treatment-alzheimer-s-disease-12954b56","doi":"10.31393/reports-vnmedical-2025-29(4)-29","journal":"Reports of Vinnytsia National Medical University","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.31393/reports-vnmedical-2025-29(4)-29","study_design":"systematic review","title":"Monoclonal antibodies for treatment Alzheimer`s disease","title_match":false,"year":2025},{"alzhub_score":26,"alzhub_url":"https://alzhub.org/study/bildgebungsanomalien-bei-alzheimer-therapie-mit-lecanemab-b85e6325","doi":"10.1055/a-2788-0873","journal":"Neuroradiologie Scan","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.1055/a-2788-0873","study_design":null,"title":"Bildgebungsanomalien bei Alzheimer-Therapie mit Lecanemab","title_match":false,"year":2026},{"alzhub_score":33,"alzhub_url":"https://alzhub.org/study/anti-amyloid-treatment-in-alzheimer-disease-updated-implications-for-42688139","doi":"10.3389/fneur.2026.1889769","journal":"Frontiers in Neurology","n_participants":null,"pmid":"42688139","source_url":"https://pubmed.ncbi.nlm.nih.gov/42688139/","study_design":null,"title":"Anti-amyloid treatment in Alzheimer disease: updated implications for patients with cerebral amyloid angiopathy and other cerebrovascular conditions","title_match":false,"year":2026},{"alzhub_score":31,"alzhub_url":"https://alzhub.org/study/therapeutic-monoclonal-antibodies-targeting-amyloid-beta-in-alzheimer-0a449f11","doi":"10.1186/s13064-026-00295-0","journal":"Discover Neuroscience","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.1186/s13064-026-00295-0","study_design":null,"title":"Therapeutic monoclonal antibodies targeting amyloid beta in Alzheimer disease current evidence clinical outcomes limitations and future directions","title_match":false,"year":2026},{"alzhub_score":28,"alzhub_url":"https://alzhub.org/study/lecanemab-leqembi-25dfc5ad","doi":"10.51731/cjht.2026.1514","journal":"Canadian Journal of Health Technologies","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.51731/cjht.2026.1514","study_design":null,"title":"Lecanemab (Leqembi)","title_match":false,"year":2026},{"alzhub_score":33,"alzhub_url":"https://alzhub.org/study/antiamyloid-antibodies-in-europe-where-are-we-now-41810890","doi":"10.1002/bcp.70526","journal":"British Journal of Clinical Pharmacology","n_participants":null,"pmid":"41810890","source_url":"https://pubmed.ncbi.nlm.nih.gov/41810890/","study_design":"clinical trial","title":"Anti\u2010amyloid antibodies in Europe: Where are we now?","title_match":false,"year":2026},{"alzhub_score":28,"alzhub_url":"https://alzhub.org/study/recomendaciones-de-uso-de-donanemab-ef1b4e53","doi":"10.22379/anc.1993","journal":"Acta neurol\u00f3gica colombiana","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.22379/anc.1993","study_design":null,"title":"Recomendaciones de uso de donanemab","title_match":false,"year":2026},{"alzhub_score":35,"alzhub_url":"https://alzhub.org/study/mouse-models-for-studying-antiamyloid-antibodyinduced-aria-41434072","doi":"10.1002/alz70861_108865","journal":"Alzheimer s & Dementia","n_participants":null,"pmid":"41434072","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12725295/","study_design":null,"title":"Mouse models for studying anti\u2010amyloid antibody\u2010induced ARIA","title_match":true,"year":2025},{"alzhub_score":25,"alzhub_url":"https://alzhub.org/study/therapierefraktarer-status-epilepticus-bei-therapie-mit-anti-amyloid-1c190b50","doi":"10.1055/a-2462-0741","journal":"Neuroradiologie Scan","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.1055/a-2462-0741","study_design":null,"title":"Therapierefrakt\u00e4rer Status epilepticus bei Therapie mit Anti-Amyloid-AK","title_match":false,"year":2025},{"alzhub_score":35,"alzhub_url":"https://alzhub.org/study/the-role-of-brain-mr-and-fdg-pet-in-the-diagnosis-of-40903623","doi":"10.1007/s00330-025-11940-3","journal":"European Radiology","n_participants":null,"pmid":"40903623","source_url":"https://pubmed.ncbi.nlm.nih.gov/40903623/","study_design":null,"title":"The role of brain MR and FDG-PET in the diagnosis of neurodegenerative disease","title_match":false,"year":2025},{"alzhub_score":42,"alzhub_url":"https://alzhub.org/study/artificial-intelligenceassisted-detection-of-amyloid-related-imaging-40738658","doi":"10.3174/ajnr.a8946","journal":"American Journal of Neuroradiology","n_participants":null,"pmid":"40738658","source_url":"https://pubmed.ncbi.nlm.nih.gov/40738658/","study_design":null,"title":"Artificial Intelligence\u2013Assisted Detection of Amyloid-Related Imaging Abnormalities: Promise and Pitfalls","title_match":true,"year":2025},{"alzhub_score":27,"alzhub_url":"https://alzhub.org/study/nieuwe-geneesmiddelen-bij-alzheimer-update-69d2f1b5","doi":"10.35351/gebu.nl.2025.11.30","journal":"Geneesmiddelenbulletin","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.35351/gebu.nl.2025.11.30","study_design":null,"title":"Nieuwe geneesmiddelen bij Alzheimer - Update","title_match":false,"year":2025},{"alzhub_score":28,"alzhub_url":"https://alzhub.org/study/perspectives-and-insights-on-anti-amyloid-immunotherapy-agents-from-08718bfc","doi":"10.5281/zenodo.21339385","journal":"Zenodo (CERN European Organization for Nuclear Research)","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.5281/zenodo.21339385","study_design":null,"title":"Perspectives and Insights on Anti-Amyloid Immunotherapy Agents: From Development to Submission of a New Drug Submission (NDS) in Canada","title_match":false,"year":2026},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/perspectives-and-insights-on-anti-amyloid-immunotherapy-agents-from-1f71b223","doi":"10.5281/zenodo.21339386","journal":"Zenodo (CERN European Organization for Nuclear Research)","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.5281/zenodo.21339386","study_design":null,"title":"Perspectives and Insights on Anti-Amyloid Immunotherapy Agents: From Development to Submission of a New Drug Submission (NDS) in Canada","title_match":false,"year":2026},{"alzhub_score":29,"alzhub_url":"https://alzhub.org/study/parallel-paths-uneven-progress-health-care-provider-and-patient-41434512","doi":"10.1002/alz70861_108349","journal":"Alzheimer s & Dementia","n_participants":null,"pmid":"41434512","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12726436/","study_design":null,"title":"Parallel Paths, Uneven Progress: Health Care Provider and Patient Perspectives on Anti\u2010Amyloid Therapies for Early AD","title_match":false,"year":2025},{"alzhub_score":28,"alzhub_url":"https://alzhub.org/study/neue-alzheimer-therapien-vortrag-zu-aria-fur-eine-sichere-mrt-41130241","doi":"10.1055/a-2690-5210","journal":"R\u00f6Fo - Fortschritte auf dem Gebiet der R\u00f6ntgenstrahlen und der bildgebenden Verfahren","n_participants":null,"pmid":"41130241","source_url":"https://pubmed.ncbi.nlm.nih.gov/41130241/","study_design":null,"title":"Neue Alzheimer-Therapien: Vortrag zu ARIA f\u00fcr eine sichere MRT-Diagnostik","title_match":true,"year":2025},{"alzhub_score":28,"alzhub_url":"https://alzhub.org/study/interview-interview-zum-thema-neue-alzheimer-therapien-warum-radiolog-41130242","doi":"10.1055/a-2690-4869","journal":"R\u00f6Fo - Fortschritte auf dem Gebiet der R\u00f6ntgenstrahlen und der bildgebenden Verfahren","n_participants":null,"pmid":"41130242","source_url":"https://pubmed.ncbi.nlm.nih.gov/41130242/","study_design":null,"title":"Interview \u2013 Interview zum Thema: Neue Alzheimer-Therapien: Warum Radiolog:innen ARIA kennen m\u00fcssen","title_match":true,"year":2025},{"alzhub_score":28,"alzhub_url":"https://alzhub.org/study/druggable-pathophysiologic-targets-in-alzheimer-disease-from-amyloid-42564518","doi":"10.12779/dnd.2026.25.3.152","journal":"Dementia and Neurocognitive Disorders","n_participants":null,"pmid":"42564518","source_url":"https://pubmed.ncbi.nlm.nih.gov/42564518/","study_design":null,"title":"Druggable Pathophysiologic Targets in Alzheimer Disease: From Amyloid and Tau to Biomarker-Guided Multimodal Therapy","title_match":false,"year":2026},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/artificial-intelligencebased-detection-of-aria-on-mri-during-42747213","doi":"10.2214/ajr.26.35514","journal":"American Journal of Roentgenology","n_participants":null,"pmid":"42747213","source_url":"https://pubmed.ncbi.nlm.nih.gov/42747213/","study_design":null,"title":"Artificial Intelligence\u2013Based Detection of ARIA on MRI During Alzheimer Disease Therapy: Expert Opinion on Responsible Clinical Integration","title_match":true,"year":2026},{"alzhub_score":27,"alzhub_url":"https://alzhub.org/study/lecanemab-autorizado-para-tratamiento-del-alzheimer-en-pacientes-que-d2104574","doi":"10.63105/pam8","journal":"Panorama actual del medicamento","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.63105/pam8","study_design":null,"title":"Lecanemab autorizado para tratamiento del Alzh\u00e9imer en pacientes que tienen una o ninguna copia de ApoE4: una reacci\u00f3n adversa grave limita su uso","title_match":false,"year":2025},{"alzhub_score":29,"alzhub_url":"https://alzhub.org/study/en-respuesta-a-avances-y-controversias-de-los-tratamientos-de-la-42435702","doi":"10.1016/j.aprim.2026.103570","journal":"Atenci\u00f3n Primaria","n_participants":null,"pmid":"42435702","source_url":"https://pubmed.ncbi.nlm.nih.gov/42435702/","study_design":null,"title":"En respuesta a \u00abAvances y controversias de los tratamientos de la enfermedad de Alzheimer\u00bb","title_match":false,"year":2026},{"alzhub_score":44,"alzhub_url":"https://alzhub.org/study/antiamyloid-therapy-and-cerebral-blood-flow-changes-on-mri-a-39805666","doi":"10.3174/ajnr.a8654","journal":"American Journal of Neuroradiology","n_participants":null,"pmid":"39805666","source_url":"https://pubmed.ncbi.nlm.nih.gov/39805666/","study_design":"longitudinal study","title":"Antiamyloid Therapy and Cerebral Blood Flow Changes on MRI: A Potential Longitudinal Biomarker of Treatment Response?","title_match":false,"year":2025},{"alzhub_score":51,"alzhub_url":"https://alzhub.org/study/a-plasma-protein-signature-for-cerebral-amyloid-angiopathy-42162487","doi":"10.1007/s00401-026-03030-5","journal":"Acta Neuropathologica","n_participants":251,"pmid":"42162487","source_url":"https://pubmed.ncbi.nlm.nih.gov/42162487/","study_design":null,"title":"A plasma protein signature for cerebral amyloid angiopathy","title_match":false,"year":2026},{"alzhub_score":27,"alzhub_url":"https://alzhub.org/study/terapia-anti-amiloide-y-enfermedad-cerebrovascular-nuevos-retos-para-7db0e4e9","doi":"10.22379/anc.2188","journal":"Acta neurol\u00f3gica colombiana","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.22379/anc.2188","study_design":null,"title":"Terapia anti \u03b2-amiloide y enfermedad cerebrovascular: nuevos retos para la neurolog\u00eda vascular","title_match":false,"year":2026},{"alzhub_score":44,"alzhub_url":"https://alzhub.org/study/real-world-challenges-in-the-mri-detection-and-classification-of-42684813","doi":"10.2214/ajr.26.35478","journal":"American Journal of Roentgenology","n_participants":null,"pmid":"42684813","source_url":"https://pubmed.ncbi.nlm.nih.gov/42684813/","study_design":"longitudinal study","title":"Real-World Challenges in the MRI Detection and Classification of Amyloid-Related Imaging Abnormalities","title_match":true,"year":2026},{"alzhub_score":28,"alzhub_url":"https://alzhub.org/study/a-novel-mouse-model-for-investigating-arias-in-response-to-anti-abeta-ff920d55","doi":"10.1016/j.cccb.2025.100475","journal":"Cerebral Circulation - Cognition and Behavior","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.1016/j.cccb.2025.100475","study_design":null,"title":"A Novel Mouse Model for Investigating ARIAs in Response to Anti-Abeta Immunotherapy","title_match":false,"year":2025},{"alzhub_score":38,"alzhub_url":"https://alzhub.org/study/neuropathological-evaluation-of-the-boston-criteria-v2-0-for-cerebral-7cc0ff47","doi":"10.1002/alz70856_105538","journal":"Alzheimer s & Dementia","n_participants":63,"pmid":null,"source_url":"https://doi.org/10.1002/alz70856_105538","study_design":null,"title":"Neuropathological evaluation of the Boston Criteria v2.0 for cerebral amyloid angiopathy in Alzheimer's disease dementia","title_match":false,"year":2025},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/imagingneuropathology-evaluation-of-amyloid-related-imaging-41517928","doi":"10.1002/alz70856_107139","journal":"Alzheimer s & Dementia","n_participants":null,"pmid":"41517928","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12789816/","study_design":"longitudinal study","title":"Imaging\u2010neuropathology evaluation of Amyloid Related Imaging Abnormality sulcal effusion in a DIAN\u2010TU\u2010001 participant treated with gantenerumab","title_match":false,"year":2025},{"alzhub_score":44,"alzhub_url":"https://alzhub.org/study/imagingneuropathology-evaluation-of-amyloid-related-imaging-41433752","doi":"10.1002/alz70862_110062","journal":"Alzheimer s & Dementia","n_participants":null,"pmid":"41433752","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12725136/","study_design":"longitudinal study","title":"Imaging\u2010neuropathology evaluation of Amyloid Related Imaging Abnormality sulcal effusion in a DIAN\u2010TU\u2010001 participant treated with gantenerumab","title_match":false,"year":2025},{"alzhub_score":26,"alzhub_url":"https://alzhub.org/study/zerebrale-amyloidangiopathie-d731ec21","doi":"10.1055/a-2572-5075","journal":"Neuroradiologie Scan","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.1055/a-2572-5075","study_design":null,"title":"Zerebrale Amyloidangiopathie","title_match":false,"year":2025},{"alzhub_score":26,"alzhub_url":"https://alzhub.org/study/zerebrale-amyloidangiopathie-3d42aad1","doi":"10.1055/a-2657-2392","journal":"Geriatrie up2date","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.1055/a-2657-2392","study_design":null,"title":"Zerebrale Amyloidangiopathie","title_match":false,"year":2025},{"alzhub_score":29,"alzhub_url":"https://alzhub.org/study/vascular-considerations-for-patients-receiving-amyloid-immunotherapy-74e40508","doi":"10.1093/geroni/igaf122.1009","journal":"Innovation in Aging","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.1093/geroni/igaf122.1009","study_design":null,"title":"Vascular Considerations for Patients Receiving Amyloid Immunotherapy","title_match":false,"year":2025},{"alzhub_score":30,"alzhub_url":"https://alzhub.org/study/clinical-evaluation-of-medicines-for-patients-with-mild-cognitive-40370495","doi":"10.1002/trc2.70100","journal":"Alzheimer s & Dementia Translational Research & Clinical Interventions","n_participants":null,"pmid":"40370495","source_url":"https://pubmed.ncbi.nlm.nih.gov/40370495/","study_design":null,"title":"Clinical evaluation of medicines for patients with mild cognitive impairment and mild dementia due to Alzheimer's disease in Japan","title_match":false,"year":2025},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/safety-and-effectiveness-of-lecanemab-in-chinese-patients-with-early-41069006","doi":"10.1097/cm9.0000000000003888","journal":"Chinese Medical Journal","n_participants":64,"pmid":"41069006","source_url":"https://pubmed.ncbi.nlm.nih.gov/41069006/","study_design":null,"title":"Safety and effectiveness of lecanemab in Chinese patients with early Alzheimer\u2019s disease: Evidence from a multidimensional real-world study","title_match":false,"year":2025},{"alzhub_score":58,"alzhub_url":"https://alzhub.org/study/clarity-ad-asian-regional-analysis-of-a-phase-iii-trial-of-lecanemab-40189473","doi":"10.1016/j.tjpad.2025.100160","journal":"The Journal of Prevention of Alzheimer s Disease","n_participants":294,"pmid":"40189473","source_url":"https://pubmed.ncbi.nlm.nih.gov/40189473/","study_design":"clinical trial","title":"Clarity AD: Asian regional analysis of a phase III trial of lecanemab in early Alzheimer's disease","title_match":false,"year":2025},{"alzhub_score":49,"alzhub_url":"https://alzhub.org/study/developing-and-validating-a-prediction-tool-for-cerebral-amyloid-40042448","doi":"10.1002/alz.14583","journal":"Alzheimer s & Dementia","n_participants":null,"pmid":"40042448","source_url":"https://pubmed.ncbi.nlm.nih.gov/40042448/","study_design":"cohort study","title":"Developing and validating a prediction tool for cerebral amyloid angiopathy neuropathological severity","title_match":false,"year":2025},{"alzhub_score":35,"alzhub_url":"https://alzhub.org/study/amyloid-solutions-lecanemab-gantenerumab-and-donanemab-in-the-2abd646d","doi":"10.1186/s41983-025-00968-3","journal":"The Egyptian Journal of Neurology Psychiatry and Neurosurgery","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.1186/s41983-025-00968-3","study_design":null,"title":"Amyloid solutions: lecanemab, gantenerumab, and donanemab in the treatment of Alzheimer's disease","title_match":false,"year":2025},{"alzhub_score":55,"alzhub_url":"https://alzhub.org/study/current-advances-and-unmet-needs-in-alzheimer-s-disease-trials-for-40528298","doi":"10.1002/alz.70258","journal":"Alzheimer s & Dementia","n_participants":null,"pmid":"40528298","source_url":"https://pubmed.ncbi.nlm.nih.gov/40528298/","study_design":"longitudinal study","title":"Current advances and unmet needs in Alzheimer's disease trials for individuals with Down syndrome: Navigating new therapeutic frontiers","title_match":false,"year":2025},{"alzhub_score":34,"alzhub_url":"https://alzhub.org/study/alzheimers-disease-basics-we-all-should-know-40639927","doi":"10.1080/01616412.2025.2529560","journal":"Neurological Research","n_participants":null,"pmid":"40639927","source_url":"https://pubmed.ncbi.nlm.nih.gov/40639927/","study_design":null,"title":"Alzheimer\u2019s disease basics: we all should know","title_match":false,"year":2025},{"alzhub_score":16,"alzhub_url":"https://alzhub.org/study/drug-drug-interaction-signals-between-anti-amyloid-antibodies-and-ba303595","doi":"10.64898/2026.09.08.26362402","journal":"medRxiv (preprint)","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.64898/2026.09.08.26362402","study_design":null,"title":"Drug-Drug Interaction Signals Between Anti-Amyloid-\u03b2 Antibodies and Antithrombotic Drugs for Amyloid-Related Imaging Abnormalities and Intracranial Hemorrhage: A FAERS Disproportionality Analysis","title_match":true,"year":2026},{"alzhub_score":37,"alzhub_url":"https://alzhub.org/study/real-world-safety-and-implementation-challenges-of-lecanemab-therapy-42449395","doi":"10.1186/s13195-026-02141-1","journal":"Alzheimer's research & therapy","n_participants":112,"pmid":"42449395","source_url":"https://pubmed.ncbi.nlm.nih.gov/42449395/","study_design":null,"title":"Real-world safety and implementation challenges of lecanemab therapy for Alzheimer's disease in South Korea: a single-center experience","title_match":false,"year":2026},{"alzhub_score":38,"alzhub_url":"https://alzhub.org/study/equity-and-budget-challenges-associated-with-the-employment-of-anti-42306480","doi":"10.1016/j.jarlif.2026.100076","journal":"JAR life","n_participants":42000,"pmid":"42306480","source_url":"https://pubmed.ncbi.nlm.nih.gov/42306480/","study_design":null,"title":"Equity and budget challenges associated with the employment of anti-amyloid monoclonal antibodies for early Alzheimer's Disease in Italy: A scenario analysis","title_match":false,"year":2026},{"alzhub_score":35,"alzhub_url":"https://alzhub.org/study/implementation-and-service-impact-of-anti-amyloid-therapy-in-a-42019137","doi":"10.1016/j.genhosppsych.2026.04.006","journal":"General hospital psychiatry","n_participants":null,"pmid":"42019137","source_url":"https://pubmed.ncbi.nlm.nih.gov/42019137/","study_design":null,"title":"Implementation and service impact of anti-amyloid therapy in a psychiatry-led dementia care program: Real-world evidence from a Japanese regional dementia center","title_match":false,"year":2026},{"alzhub_score":56,"alzhub_url":"https://alzhub.org/study/practical-guide-of-the-korean-association-for-geriatric-psychiatry-to-40696527","doi":"10.3346/jkms.2025.40.e215","journal":"Journal of Korean medical science","n_participants":null,"pmid":"40696527","source_url":"https://pubmed.ncbi.nlm.nih.gov/40696527/","study_design":"randomized controlled trial","title":"Practical Guide of the Korean Association for Geriatric Psychiatry to Anti-Amyloid Monoclonal Antibody Therapy for Alzheimer's Disease: Focused on Lecanemab","title_match":false,"year":2025},{"alzhub_score":51,"alzhub_url":"https://alzhub.org/study/lecanemab-appropriate-use-recommendations-37357276","doi":"10.14283/jpad.2023.30","journal":"The Journal of Prevention of Alzheimer s Disease","n_participants":null,"pmid":"37357276","source_url":"https://pubmed.ncbi.nlm.nih.gov/37357276/","study_design":null,"title":"Lecanemab: Appropriate Use Recommendations","title_match":false,"year":2023},{"alzhub_score":55,"alzhub_url":"https://alzhub.org/study/amyloid-related-imaging-abnormalities-in-amyloid-modifying-21784348","doi":"10.1016/j.jalz.2011.05.2351","journal":"Alzheimer s & Dementia","n_participants":null,"pmid":"21784348","source_url":"https://pubmed.ncbi.nlm.nih.gov/21784348/","study_design":null,"title":"Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer\u2019s Association Research Roundtable Workgroup","title_match":true,"year":2011},{"alzhub_score":62,"alzhub_url":"https://alzhub.org/study/phase-3-trials-of-solanezumab-for-mild-to-moderate-alzheimer-s-disease-24450890","doi":"10.1056/nejmoa1312889","journal":"New England Journal of Medicine","n_participants":null,"pmid":"24450890","source_url":"https://pubmed.ncbi.nlm.nih.gov/24450890/","study_design":null,"title":"Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease","title_match":false,"year":2014},{"alzhub_score":81,"alzhub_url":"https://alzhub.org/study/the-fda-approved-anti-amyloid-monoclonal-antibodies-for-the-treatment-38017568","doi":"10.1186/s40001-023-01512-w","journal":"European journal of medical research","n_participants":4471,"pmid":"38017568","source_url":"https://pubmed.ncbi.nlm.nih.gov/38017568/","study_design":"systematic review","title":"The FDA-approved anti-amyloid-\u03b2 monoclonal antibodies for the treatment of Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials","title_match":false,"year":2023},{"alzhub_score":83,"alzhub_url":"https://alzhub.org/study/a-trial-of-gantenerumab-or-solanezumab-in-dominantly-inherited-34155411","doi":"10.1038/s41591-021-01369-8","journal":"Nature medicine","n_participants":null,"pmid":"34155411","source_url":"https://pubmed.ncbi.nlm.nih.gov/34155411/","study_design":null,"title":"A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease","title_match":false,"year":2021},{"alzhub_score":60,"alzhub_url":"https://alzhub.org/study/safety-and-efficacy-of-sargramostim-gm-csf-in-the-treatment-of-33778150","doi":"10.1002/trc2.12158","journal":"Alzheimer's & dementia (New York, N. Y.)","n_participants":20,"pmid":"33778150","source_url":"https://pubmed.ncbi.nlm.nih.gov/33778150/","study_design":null,"title":"Safety and efficacy of sargramostim (GM-CSF) in the treatment of Alzheimer's disease","title_match":false,"year":2021},{"alzhub_score":79,"alzhub_url":"https://alzhub.org/study/trial-of-solanezumab-in-preclinical-alzheimer-s-disease-37458272","doi":"10.1056/nejmoa2305032","journal":"The New England journal of medicine","n_participants":1169,"pmid":"37458272","source_url":"https://pubmed.ncbi.nlm.nih.gov/37458272/","study_design":"clinical trial","title":"Trial of Solanezumab in Preclinical Alzheimer's Disease","title_match":false,"year":2023},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/anti-amyloid-monoclonal-antibodies-for-the-treatment-of-alzheimer-s-37955845","doi":"10.1007/s40259-023-00633-2","journal":"BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy","n_participants":null,"pmid":"37955845","source_url":"https://pubmed.ncbi.nlm.nih.gov/37955845/","study_design":null,"title":"Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer's Disease","title_match":false,"year":2024},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/anti-amyloid-monoclonal-antibodies-for-alzheimer-s-disease-pitfalls-28967385","doi":"10.1016/j.biopsych.2017.08.010","journal":"Biological psychiatry","n_participants":null,"pmid":"28967385","source_url":"https://pubmed.ncbi.nlm.nih.gov/28967385/","study_design":null,"title":"Anti-Amyloid-\u03b2 Monoclonal Antibodies for Alzheimer's Disease: Pitfalls and Promise","title_match":false,"year":2018},{"alzhub_score":53,"alzhub_url":"https://alzhub.org/study/amyloid-related-imaging-abnormalities-aria-radiological-biological-37280110","doi":"10.1093/brain/awad188","journal":"Brain : a journal of neurology","n_participants":null,"pmid":"37280110","source_url":"https://pubmed.ncbi.nlm.nih.gov/37280110/","study_design":null,"title":"Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics","title_match":true,"year":2023},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/aducanumab-appropriate-use-recommendations-34585212","doi":"10.14283/jpad.2021.41","journal":"The journal of prevention of Alzheimer's disease","n_participants":null,"pmid":"34585212","source_url":"https://pubmed.ncbi.nlm.nih.gov/34585212/","study_design":null,"title":"Aducanumab: Appropriate Use Recommendations","title_match":false,"year":2021},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/anti-amyloid-monoclonal-antibodies-are-transformative-treatments-that-37060386","doi":"10.1007/s40265-023-01858-9","journal":"Drugs","n_participants":null,"pmid":"37060386","source_url":"https://pubmed.ncbi.nlm.nih.gov/37060386/","study_design":null,"title":"Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics","title_match":false,"year":2023},{"alzhub_score":84,"alzhub_url":"https://alzhub.org/study/effects-of-monoclonal-antibodies-against-amyloid-on-clinical-and-33831607","doi":"10.1016/j.arr.2021.101339","journal":"Ageing research reviews","n_participants":12585,"pmid":"33831607","source_url":"https://pubmed.ncbi.nlm.nih.gov/33831607/","study_design":"meta-analysis","title":"Effects of monoclonal antibodies against amyloid-\u03b2 on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer's disease","title_match":false,"year":2021},{"alzhub_score":54,"alzhub_url":"https://alzhub.org/study/anti-amyloid-autoantibodies-in-cerebral-amyloid-angiopathy-related-23625526","doi":"10.1002/ana.23857","journal":"Annals of neurology","n_participants":null,"pmid":"23625526","source_url":"https://pubmed.ncbi.nlm.nih.gov/23625526/","study_design":"case-control study","title":"Anti-amyloid \u03b2 autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies","title_match":false,"year":2013},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/aducanumab-appropriate-use-recommendations-update-35542993","doi":"10.14283/jpad.2022.34","journal":"The journal of prevention of Alzheimer's disease","n_participants":null,"pmid":"35542993","source_url":"https://pubmed.ncbi.nlm.nih.gov/35542993/","study_design":null,"title":"Aducanumab: Appropriate Use Recommendations Update","title_match":false,"year":2022},{"alzhub_score":40,"alzhub_url":"https://alzhub.org/study/detection-and-management-of-amyloid-related-imaging-abnormalities-in-35542992","doi":"10.14283/jpad.2022.21","journal":"The journal of prevention of Alzheimer's disease","n_participants":null,"pmid":"35542992","source_url":"https://pubmed.ncbi.nlm.nih.gov/35542992/","study_design":null,"title":"Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer's Disease Treated with Anti-Amyloid Beta Therapy","title_match":true,"year":2022},{"alzhub_score":53,"alzhub_url":"https://alzhub.org/study/first-in-human-double-blind-placebo-controlled-single-dose-escalation-29067304","doi":"10.1016/j.trci.2016.06.002","journal":"Alzheimer's & dementia (New York, N. Y.)","n_participants":null,"pmid":"29067304","source_url":"https://pubmed.ncbi.nlm.nih.gov/29067304/","study_design":null,"title":"First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease","title_match":false,"year":2016},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/anti-amyloid-immunotherapies-for-alzheimer-s-disease-a-2023-clinical-37490245","doi":"10.1007/s13311-023-01405-0","journal":"Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics","n_participants":null,"pmid":"37490245","source_url":"https://pubmed.ncbi.nlm.nih.gov/37490245/","study_design":"clinical trial","title":"Anti-Amyloid Immunotherapies for Alzheimer's Disease: A 2023 Clinical Update","title_match":false,"year":2023},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/risk-factors-in-developing-amyloid-related-imaging-abnormalities-aria-38312931","doi":"10.3389/fnins.2024.1326784","journal":"Frontiers in neuroscience","n_participants":null,"pmid":"38312931","source_url":"https://pubmed.ncbi.nlm.nih.gov/38312931/","study_design":null,"title":"Risk factors in developing amyloid related imaging abnormalities (ARIA) and clinical implications","title_match":true,"year":2024},{"alzhub_score":66,"alzhub_url":"https://alzhub.org/study/safety-and-tolerability-of-ban2401-a-clinical-study-in-alzheimer-s-27048170","doi":"10.1186/s13195-016-0181-2","journal":"Alzheimer's research & therapy","n_participants":null,"pmid":"27048170","source_url":"https://pubmed.ncbi.nlm.nih.gov/27048170/","study_design":null,"title":"Safety and tolerability of BAN2401--a clinical study in Alzheimer's disease with a protofibril selective A\u03b2 antibody","title_match":false,"year":2016},{"alzhub_score":40,"alzhub_url":"https://alzhub.org/study/apoe-immunotherapy-reduces-cerebral-amyloid-angiopathy-and-amyloid-33597265","doi":"10.1126/scitranslmed.abd7522","journal":"Science translational medicine","n_participants":null,"pmid":"33597265","source_url":"https://pubmed.ncbi.nlm.nih.gov/33597265/","study_design":null,"title":"APOE immunotherapy reduces cerebral amyloid angiopathy and amyloid plaques while improving cerebrovascular function","title_match":false,"year":2021},{"alzhub_score":47,"alzhub_url":"https://alzhub.org/study/aria-in-patients-treated-with-lecanemab-ban2401-in-a-phase-2-study-in-36949897","doi":"10.1002/trc2.12377","journal":"Alzheimer's & dementia (New York, N. Y.)","n_participants":null,"pmid":"36949897","source_url":"https://pubmed.ncbi.nlm.nih.gov/36949897/","study_design":"clinical trial","title":"ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease","title_match":true,"year":2023},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/amyloid-a-immunotherapy-induced-microhemorrhages-are-associated-with-37649100","doi":"10.1186/s13024-023-00649-w","journal":"Molecular neurodegeneration","n_participants":null,"pmid":"37649100","source_url":"https://pubmed.ncbi.nlm.nih.gov/37649100/","study_design":null,"title":"Amyloid-\u03b2 (A\u03b2) immunotherapy induced microhemorrhages are associated with activated perivascular macrophages and peripheral monocyte recruitment in Alzheimer's disease mice","title_match":false,"year":2023},{"alzhub_score":47,"alzhub_url":"https://alzhub.org/study/clinical-development-of-aducanumab-an-anti-a-human-monoclonal-29181491","doi":"10.14283/jpad.2017.39","journal":"The journal of prevention of Alzheimer's disease","n_participants":196,"pmid":"29181491","source_url":"https://pubmed.ncbi.nlm.nih.gov/29181491/","study_design":null,"title":"Clinical Development of Aducanumab, an Anti-A\u03b2 Human Monoclonal Antibody Being Investigated for the Treatment of Early Alzheimer's Disease","title_match":false,"year":2017},{"alzhub_score":71,"alzhub_url":"https://alzhub.org/study/safety-and-efficacy-of-monoclonal-antibodies-for-alzheimer-s-disease-35275549","doi":"10.3233/jad-220046","journal":"Journal of Alzheimer's disease : JAD","n_participants":null,"pmid":"35275549","source_url":"https://pubmed.ncbi.nlm.nih.gov/35275549/","study_design":"meta-analysis","title":"Safety and Efficacy of Monoclonal Antibodies for Alzheimer's Disease: A Systematic Review and Meta-Analysis of Published and Unpublished Clinical Trials","title_match":false,"year":2022},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/amyloid-related-imaging-abnormalities-manifestations-metrics-and-39794509","doi":"10.1038/s41582-024-01053-8","journal":"Nature reviews. Neurology","n_participants":null,"pmid":"39794509","source_url":"https://pubmed.ncbi.nlm.nih.gov/39794509/","study_design":null,"title":"Amyloid-related imaging abnormalities: manifestations, metrics and mechanisms","title_match":true,"year":2025},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/bapineuzumab-and-solanezumab-for-alzheimer-s-disease-is-the-amyloid-23574434","doi":"10.1517/14712598.2013.789856","journal":"Expert opinion on biological therapy","n_participants":null,"pmid":"23574434","source_url":"https://pubmed.ncbi.nlm.nih.gov/23574434/","study_design":null,"title":"Bapineuzumab and solanezumab for Alzheimer's disease: is the 'amyloid cascade hypothesis' still alive?","title_match":false,"year":2013},{"alzhub_score":59,"alzhub_url":"https://alzhub.org/study/efficacy-and-safety-of-anti-amyloid-immunotherapy-for-alzheimer-s-29296624","doi":"10.1002/acn3.469","journal":"Annals of clinical and translational neurology","n_participants":5141,"pmid":"29296624","source_url":"https://pubmed.ncbi.nlm.nih.gov/29296624/","study_design":null,"title":"Efficacy and safety of anti-amyloid- \u03b2 immunotherapy for Alzheimer's disease: a systematic review and network meta-analysis","title_match":false,"year":2017},{"alzhub_score":79,"alzhub_url":"https://alzhub.org/study/efficacy-and-safety-of-anti-amyloid-monoclonal-antibodies-in-current-37423541","doi":"10.1016/j.arr.2023.102012","journal":"Ageing research reviews","n_participants":14980,"pmid":"37423541","source_url":"https://pubmed.ncbi.nlm.nih.gov/37423541/","study_design":"meta-analysis","title":"Efficacy and safety of anti-amyloid-\u03b2 monoclonal antibodies in current Alzheimer's disease phase III clinical trials: A systematic review and interactive web app-based meta-analysis","title_match":false,"year":2023},{"alzhub_score":71,"alzhub_url":"https://alzhub.org/study/high-clearance-anti-amyloid-immunotherapies-in-alzheimer-s-disease-36184326","doi":"10.1016/j.neurol.2022.06.012","journal":"Revue neurologique","n_participants":null,"pmid":"36184326","source_url":"https://pubmed.ncbi.nlm.nih.gov/36184326/","study_design":"meta-analysis","title":"High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects","title_match":false,"year":2022},{"alzhub_score":40,"alzhub_url":"https://alzhub.org/study/anti-a-autoantibodies-in-amyloid-related-imaging-abnormalities-aria-26441825","doi":"10.3389/fneur.2015.00207","journal":"Frontiers in neurology","n_participants":null,"pmid":"26441825","source_url":"https://pubmed.ncbi.nlm.nih.gov/26441825/","study_design":null,"title":"Anti-A\u03b2 Autoantibodies in Amyloid Related Imaging Abnormalities (ARIA): Candidate Biomarker for Immunotherapy in Alzheimer's Disease and Cerebral Amyloid Angiopathy","title_match":true,"year":2015},{"alzhub_score":83,"alzhub_url":"https://alzhub.org/study/donanemab-for-alzheimer-s-disease-a-systematic-review-of-clinical-36611492","doi":"10.3390/healthcare11010032","journal":"Healthcare (Basel, Switzerland)","n_participants":396,"pmid":"36611492","source_url":"https://pubmed.ncbi.nlm.nih.gov/36611492/","study_design":"systematic review","title":"Donanemab for Alzheimer's Disease: A Systematic Review of Clinical Trials","title_match":false,"year":2022},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/donanemab-population-pharmacokinetics-amyloid-plaque-reduction-and-36805552","doi":"10.1002/cpt.2875","journal":"Clinical pharmacology and therapeutics","n_participants":null,"pmid":"36805552","source_url":"https://pubmed.ncbi.nlm.nih.gov/36805552/","study_design":null,"title":"Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease","title_match":false,"year":2023},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/vascular-alterations-in-pdapp-mice-after-anti-a-immunotherapy-23583235","doi":"10.1016/j.jalz.2012.11.010","journal":"Alzheimer's & dementia : the journal of the Alzheimer's Association","n_participants":345,"pmid":"23583235","source_url":"https://pubmed.ncbi.nlm.nih.gov/23583235/","study_design":null,"title":"Vascular alterations in PDAPP mice after anti-A\u03b2 immunotherapy: Implications for amyloid-related imaging abnormalities","title_match":true,"year":2013},{"alzhub_score":81,"alzhub_url":"https://alzhub.org/study/safety-and-efficacy-of-anti-amyloid-immunotherapy-in-alzheimer-s-28025724","doi":"10.1007/s11481-016-9722-5","journal":"Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology","n_participants":5554,"pmid":"28025724","source_url":"https://pubmed.ncbi.nlm.nih.gov/28025724/","study_design":null,"title":"Safety and Efficacy of Anti-Amyloid-\u03b2 Immunotherapy in Alzheimer's Disease: A Systematic Review and Meta-Analysis","title_match":false,"year":2017},{"alzhub_score":50,"alzhub_url":"https://alzhub.org/study/amyloid-related-imaging-abnormalities-haemosiderin-aria-h-in-patients-25669746","doi":"10.1136/jnnp-2014-309493","journal":"Journal of neurology, neurosurgery, and psychiatry","n_participants":262,"pmid":"25669746","source_url":"https://pubmed.ncbi.nlm.nih.gov/25669746/","study_design":"open-label trial","title":"Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer's disease treated with bapineuzumab: a historical, prospective secondary analysis","title_match":true,"year":2016},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/three-major-effects-of-apoe-4-on-a-immunotherapy-induced-aria-38756535","doi":"10.3389/fnagi.2024.1412006","journal":"Frontiers in aging neuroscience","n_participants":null,"pmid":"38756535","source_url":"https://pubmed.ncbi.nlm.nih.gov/38756535/","study_design":null,"title":"Three major effects of APOE \u03b54 on A\u03b2 immunotherapy induced ARIA","title_match":true,"year":2024},{"alzhub_score":48,"alzhub_url":"https://alzhub.org/study/amyloid-beta-antibody-binding-to-cerebral-amyloid-angiopathy-fibrils-38740836","doi":"10.1038/s41598-024-61691-2","journal":"Scientific reports","n_participants":null,"pmid":"38740836","source_url":"https://pubmed.ncbi.nlm.nih.gov/38740836/","study_design":null,"title":"Amyloid-beta antibody binding to cerebral amyloid angiopathy fibrils and risk for amyloid-related imaging abnormalities","title_match":true,"year":2024},{"alzhub_score":78,"alzhub_url":"https://alzhub.org/study/central-review-of-amyloid-related-imaging-abnormalities-in-two-phase-28269765","doi":"10.3233/jad-160216","journal":"Journal of Alzheimer's disease : JAD","n_participants":242,"pmid":"28269765","source_url":"https://pubmed.ncbi.nlm.nih.gov/28269765/","study_design":null,"title":"Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer's Disease Patients","title_match":true,"year":2017},{"alzhub_score":47,"alzhub_url":"https://alzhub.org/study/transferrin-receptor-targeted-anti-amyloid-antibody-enhances-brain-40773560","doi":"10.1126/science.ads3204","journal":"Science (New York, N.Y.)","n_participants":null,"pmid":"40773560","source_url":"https://pubmed.ncbi.nlm.nih.gov/40773560/","study_design":null,"title":"Transferrin receptor-targeted anti-amyloid antibody enhances brain delivery and mitigates ARIA","title_match":true,"year":2025},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/alzheimer-disease-anti-amyloid-immunotherapies-imaging-39179297","doi":"10.3174/ajnr.a8469","journal":"AJNR. American journal of neuroradiology","n_participants":null,"pmid":"39179297","source_url":"https://pubmed.ncbi.nlm.nih.gov/39179297/","study_design":null,"title":"Alzheimer Disease Anti-Amyloid Immunotherapies: Imaging Recommendations and Practice Considerations for Monitoring of Amyloid-Related Imaging Abnormalities","title_match":true,"year":2025},{"alzhub_score":38,"alzhub_url":"https://alzhub.org/study/the-future-of-anti-amyloid-trials-32463066","doi":"10.14283/jpad.2020.24","journal":"The journal of prevention of Alzheimer's disease","n_participants":null,"pmid":"32463066","source_url":"https://pubmed.ncbi.nlm.nih.gov/32463066/","study_design":null,"title":"The Future of Anti-Amyloid Trials","title_match":false,"year":2020},{"alzhub_score":72,"alzhub_url":"https://alzhub.org/study/critical-assessment-of-anti-amyloid-monoclonal-antibodies-effects-in-39468148","doi":"10.1038/s41598-024-75204-8","journal":"Scientific reports","n_participants":null,"pmid":"39468148","source_url":"https://pubmed.ncbi.nlm.nih.gov/39468148/","study_design":"systematic review","title":"Critical assessment of anti-amyloid-\u03b2 monoclonal antibodies effects in Alzheimer's disease: a systematic review and meta-analysis highlighting target engagement and clinical meaningfulness","title_match":false,"year":2024},{"alzhub_score":40,"alzhub_url":"https://alzhub.org/study/a-immunotherapy-for-alzheimer-s-disease-effects-on-apoe-and-cerebral-25195061","doi":"10.1007/s00401-014-1340-9","journal":"Acta neuropathologica","n_participants":null,"pmid":"25195061","source_url":"https://pubmed.ncbi.nlm.nih.gov/25195061/","study_design":null,"title":"A\u03b2 immunotherapy for Alzheimer's disease: effects on apoE and cerebral vasculopathy","title_match":false,"year":2014},{"alzhub_score":57,"alzhub_url":"https://alzhub.org/study/an-mri-rating-scale-for-amyloid-related-imaging-abnormalities-with-23436056","doi":"10.3174/ajnr.a3475","journal":"AJNR. American journal of neuroradiology","n_participants":20,"pmid":"23436056","source_url":"https://pubmed.ncbi.nlm.nih.gov/23436056/","study_design":null,"title":"An MRI rating scale for amyloid-related imaging abnormalities with edema or effusion","title_match":true,"year":2013},{"alzhub_score":62,"alzhub_url":"https://alzhub.org/study/safety-tolerability-and-pharmacokinetics-of-crenezumab-in-patients-32568196","doi":"10.3233/jad-200134","journal":"Journal of Alzheimer's disease : JAD","n_participants":21,"pmid":"32568196","source_url":"https://pubmed.ncbi.nlm.nih.gov/32568196/","study_design":"open-label trial","title":"Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients with Mild-to-Moderate Alzheimer's Disease Treated with Escalating Doses for up to 133 Weeks","title_match":false,"year":2020},{"alzhub_score":62,"alzhub_url":"https://alzhub.org/study/amyloid-related-imaging-abnormalities-from-trials-of-solanezumab-for-27239538","doi":"10.1016/j.dadm.2016.02.004","journal":"Alzheimer's & dementia (Amsterdam, Netherlands)","n_participants":2042,"pmid":"27239538","source_url":"https://pubmed.ncbi.nlm.nih.gov/27239538/","study_design":"open-label trial","title":"Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer's disease","title_match":true,"year":2016},{"alzhub_score":76,"alzhub_url":"https://alzhub.org/study/safety-and-efficacy-of-lecanemab-for-alzheimer-s-disease-a-systematic-37213538","doi":"10.3389/fnagi.2023.1169499","journal":"Frontiers in aging neuroscience","n_participants":null,"pmid":"37213538","source_url":"https://pubmed.ncbi.nlm.nih.gov/37213538/","study_design":"systematic review","title":"Safety and efficacy of lecanemab for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials","title_match":false,"year":2023},{"alzhub_score":57,"alzhub_url":"https://alzhub.org/study/secondary-prevention-of-alzheimer-s-dementia-neuroimaging-30376881","doi":"10.1186/s13195-018-0438-z","journal":"Alzheimer's research & therapy","n_participants":null,"pmid":"30376881","source_url":"https://pubmed.ncbi.nlm.nih.gov/30376881/","study_design":"longitudinal study","title":"Secondary prevention of Alzheimer's dementia: neuroimaging contributions","title_match":false,"year":2018},{"alzhub_score":74,"alzhub_url":"https://alzhub.org/study/first-in-human-safety-and-long-term-exposure-data-for-aab-003-pf-26925577","doi":"10.1186/s13195-016-0177-y","journal":"Alzheimer's research & therapy","n_participants":52,"pmid":"26925577","source_url":"https://pubmed.ncbi.nlm.nih.gov/26925577/","study_design":"open-label trial","title":"First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer's disease","title_match":false,"year":2016},{"alzhub_score":59,"alzhub_url":"https://alzhub.org/study/cerebral-amyloid-angiopathy-related-atraumatic-convexal-subarachnoid-25735919","doi":"10.1038/jcbfm.2015.25","journal":"Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism","n_participants":22,"pmid":"25735919","source_url":"https://pubmed.ncbi.nlm.nih.gov/25735919/","study_design":"cohort study","title":"Cerebral amyloid angiopathy-related atraumatic convexal subarachnoid hemorrhage: an ARIA before the tsunami","title_match":true,"year":2015},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/amyloid-a-immunotherapy-induced-microhemorrhages-are-linked-to-39434125","doi":"10.1186/s13024-024-00758-0","journal":"Molecular neurodegeneration","n_participants":null,"pmid":"39434125","source_url":"https://pubmed.ncbi.nlm.nih.gov/39434125/","study_design":null,"title":"Amyloid-\u03b2 (A\u03b2) immunotherapy induced microhemorrhages are linked to vascular inflammation and cerebrovascular damage in a mouse model of Alzheimer's disease","title_match":false,"year":2024},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/lecanemab-for-early-alzheimer-s-disease-appropriate-use-40011173","doi":"10.1016/j.tjpad.2025.100094","journal":"The journal of prevention of Alzheimer's disease","n_participants":null,"pmid":"40011173","source_url":"https://pubmed.ncbi.nlm.nih.gov/40011173/","study_design":null,"title":"Lecanemab for early Alzheimer's disease: Appropriate use recommendations from the French federation of memory clinics","title_match":false,"year":2025},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/proteolytic-processing-of-neuregulin-1-27393467","doi":"10.1016/j.brainresbull.2016.07.003","journal":"Brain research bulletin","n_participants":null,"pmid":"27393467","source_url":"https://pubmed.ncbi.nlm.nih.gov/27393467/","study_design":null,"title":"Proteolytic processing of Neuregulin-1","title_match":false,"year":2016},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/amyloid-related-imaging-abnormalities-aria-in-immunotherapy-trials-27031492","doi":"10.3233/jad-160122","journal":"Journal of Alzheimer's disease : JAD","n_participants":null,"pmid":"27031492","source_url":"https://pubmed.ncbi.nlm.nih.gov/27031492/","study_design":"clinical trial","title":"Amyloid-Related Imaging Abnormalities (ARIA) in Immunotherapy Trials for Alzheimer's Disease: Need for Prognostic Biomarkers?","title_match":true,"year":2016},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/prodromal-alzheimer-s-disease-presenting-as-cerebral-amyloid-25537009","doi":"10.3233/jad-142376","journal":"Journal of Alzheimer's disease : JAD","n_participants":null,"pmid":"25537009","source_url":"https://pubmed.ncbi.nlm.nih.gov/25537009/","study_design":null,"title":"Prodromal Alzheimer's disease presenting as cerebral amyloid angiopathy-related inflammation with spontaneous amyloid-related imaging abnormalities and high cerebrospinal fluid anti-A\u03b2 autoantibodies","title_match":true,"year":2015},{"alzhub_score":40,"alzhub_url":"https://alzhub.org/study/aducanumab-making-a-comeback-in-alzheimer-s-disease-an-old-wine-in-a-35231697","doi":"10.1016/j.biopha.2022.112746","journal":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","n_participants":null,"pmid":"35231697","source_url":"https://pubmed.ncbi.nlm.nih.gov/35231697/","study_design":null,"title":"\"Aducanumab\" making a comeback in Alzheimer's disease: An old wine in a new bottle","title_match":false,"year":2022},{"alzhub_score":71,"alzhub_url":"https://alzhub.org/study/implications-of-the-approval-of-lecanemab-for-alzheimer-disease-37295957","doi":"10.1212/wnl.0000000000207438","journal":"Neurology","n_participants":null,"pmid":"37295957","source_url":"https://pubmed.ncbi.nlm.nih.gov/37295957/","study_design":"clinical trial","title":"Implications of the Approval of Lecanemab for Alzheimer Disease Patient Care: Incremental Step or Paradigm Shift?","title_match":false,"year":2023},{"alzhub_score":84,"alzhub_url":"https://alzhub.org/study/comparative-efficacy-and-safety-of-monoclonal-antibodies-for-38429615","doi":"10.1007/s40263-024-01067-2","journal":"CNS drugs","n_participants":21087,"pmid":"38429615","source_url":"https://pubmed.ncbi.nlm.nih.gov/38429615/","study_design":"meta-analysis","title":"Comparative Efficacy and Safety of Monoclonal Antibodies for Cognitive Decline in Patients with Alzheimer's Disease: A Systematic Review and Network Meta-Analysis","title_match":false,"year":2024},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/anti-amyloid-therapy-ad-and-aria-untangling-the-role-of-caa-37959255","doi":"10.3390/jcm12216792","journal":"Journal of clinical medicine","n_participants":null,"pmid":"37959255","source_url":"https://pubmed.ncbi.nlm.nih.gov/37959255/","study_design":null,"title":"Anti-Amyloid Therapy, AD, and ARIA: Untangling the Role of CAA","title_match":true,"year":2023},{"alzhub_score":59,"alzhub_url":"https://alzhub.org/study/post-marketing-safety-concerns-with-lecanemab-a-pharmacovigilance-39780222","doi":"10.1186/s13195-024-01669-4","journal":"Alzheimer's research & therapy","n_participants":193,"pmid":"39780222","source_url":"https://pubmed.ncbi.nlm.nih.gov/39780222/","study_design":null,"title":"Post-marketing safety concerns with lecanemab: a pharmacovigilance study based on the FDA Adverse Event Reporting System database","title_match":false,"year":2025},{"alzhub_score":57,"alzhub_url":"https://alzhub.org/study/retinal-image-analytics-detects-white-matter-hyperintensities-in-30656187","doi":"10.1002/acn3.688","journal":"Annals of clinical and translational neurology","n_participants":180,"pmid":"30656187","source_url":"https://pubmed.ncbi.nlm.nih.gov/30656187/","study_design":"cross-sectional","title":"Retinal image analytics detects white matter hyperintensities in healthy adults","title_match":false,"year":2019},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/the-role-of-neuroinflammation-in-cerebral-amyloid-angiopathy-39608058","doi":"10.1016/j.ebiom.2024.105466","journal":"EBioMedicine","n_participants":null,"pmid":"39608058","source_url":"https://pubmed.ncbi.nlm.nih.gov/39608058/","study_design":null,"title":"The role of neuroinflammation in cerebral amyloid angiopathy","title_match":false,"year":2024},{"alzhub_score":48,"alzhub_url":"https://alzhub.org/study/clearance-of-interstitial-fluid-isf-and-csf-clic-group-part-of-37897797","doi":"10.1002/alz.13512","journal":"Alzheimer's & dementia : the journal of the Alzheimer's Association","n_participants":null,"pmid":"37897797","source_url":"https://pubmed.ncbi.nlm.nih.gov/37897797/","study_design":null,"title":"Clearance of interstitial fluid (ISF) and CSF (CLIC) group-part of Vascular Professional Interest Area (PIA), updates in 2022-2023. Cerebrovascular disease and the failure of elimination of Amyloid-\u03b2 from the brain and retina with age and Alzheimer's disease: Opportunities for therapy","title_match":false,"year":2024},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/clinical-evaluation-of-amyloid-related-imaging-abnormalities-in-30412493","doi":"10.3233/jad-180675","journal":"Journal of Alzheimer's disease : JAD","n_participants":null,"pmid":"30412493","source_url":"https://pubmed.ncbi.nlm.nih.gov/30412493/","study_design":null,"title":"Clinical Evaluation of Amyloid-Related Imaging Abnormalities in Bapineuzumab Phase III Studies","title_match":true,"year":2018},{"alzhub_score":66,"alzhub_url":"https://alzhub.org/study/safety-and-efficacy-of-active-and-passive-immunotherapy-in-mild-to-30904037","doi":"10.25011/cim.v42i1.32393","journal":"Clinical and investigative medicine. Medecine clinique et experimentale","n_participants":null,"pmid":"30904037","source_url":"https://pubmed.ncbi.nlm.nih.gov/30904037/","study_design":"systematic review","title":"Safety and efficacy of active and passive immunotherapy in mild-to-moderate Alzheimer's disease: A systematic review and network meta-analysis","title_match":false,"year":2019},{"alzhub_score":69,"alzhub_url":"https://alzhub.org/study/monoclonal-therapy-with-lecanemab-in-the-treatment-of-mild-alzheimer-39638097","doi":"10.1016/j.arr.2024.102620","journal":"Ageing research reviews","n_participants":null,"pmid":"39638097","source_url":"https://pubmed.ncbi.nlm.nih.gov/39638097/","study_design":"systematic review","title":"Monoclonal therapy with lecanemab in the treatment of mild Alzheimer's disease: A systematic review and meta-analysis","title_match":false,"year":2025},{"alzhub_score":69,"alzhub_url":"https://alzhub.org/study/first-administration-of-the-fc-attenuated-anti-amyloid-antibody-25789616","doi":"10.1371/journal.pone.0098153","journal":"PloS one","n_participants":18,"pmid":"25789616","source_url":"https://pubmed.ncbi.nlm.nih.gov/25789616/","study_design":"open-label trial","title":"First administration of the Fc-attenuated anti-\u03b2 amyloid antibody GSK933776 to patients with mild Alzheimer's disease: a randomized, placebo-controlled study","title_match":false,"year":2015},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/bispecific-brain-penetrant-antibodies-for-treatment-of-alzheimer-s-40425446","doi":"10.1016/j.tjpad.2025.100214","journal":"The journal of prevention of Alzheimer's disease","n_participants":null,"pmid":"40425446","source_url":"https://pubmed.ncbi.nlm.nih.gov/40425446/","study_design":null,"title":"Bispecific brain-penetrant antibodies for treatment of Alzheimer's disease","title_match":false,"year":2025},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/the-impact-of-anti-amyloid-immunotherapies-on-stroke-care-38592119","doi":"10.3390/jcm13051245","journal":"Journal of clinical medicine","n_participants":null,"pmid":"38592119","source_url":"https://pubmed.ncbi.nlm.nih.gov/38592119/","study_design":null,"title":"The Impact of Anti-Amyloid Immunotherapies on Stroke Care","title_match":false,"year":2024},{"alzhub_score":86,"alzhub_url":"https://alzhub.org/study/efficacy-of-anti-amyloid-monoclonal-antibody-therapy-in-early-37978096","doi":"10.1007/s10072-023-07194-w","journal":"Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","n_participants":15275,"pmid":"37978096","source_url":"https://pubmed.ncbi.nlm.nih.gov/37978096/","study_design":null,"title":"Efficacy of anti-amyloid-\u00df monoclonal antibody therapy in early Alzheimer's disease: a systematic review and meta-analysis","title_match":false,"year":2024},{"alzhub_score":66,"alzhub_url":"https://alzhub.org/study/longitudinal-accumulation-of-cerebral-microhemorrhages-in-dominantly-33495373","doi":"10.1212/wnl.0000000000011542","journal":"Neurology","n_participants":310,"pmid":"33495373","source_url":"https://pubmed.ncbi.nlm.nih.gov/33495373/","study_design":"cross-sectional","title":"Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease","title_match":false,"year":2021},{"alzhub_score":57,"alzhub_url":"https://alzhub.org/study/chronic-verubecestat-treatment-suppresses-amyloid-accumulation-in-28800329","doi":"10.3233/jad-170056","journal":"Journal of Alzheimer's disease : JAD","n_participants":null,"pmid":"28800329","source_url":"https://pubmed.ncbi.nlm.nih.gov/28800329/","study_design":"longitudinal study","title":"Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-A\u03b2PPswe Mice Without Inducing Microhemorrhage","title_match":false,"year":2017},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/spontaneous-aria-amyloid-related-imaging-abnormalities-and-cerebral-25408217","doi":"10.3233/jad-142325","journal":"Journal of Alzheimer's disease : JAD","n_participants":null,"pmid":"25408217","source_url":"https://pubmed.ncbi.nlm.nih.gov/25408217/","study_design":null,"title":"Spontaneous ARIA (amyloid-related imaging abnormalities) and cerebral amyloid angiopathy related inflammation in presenilin 1-associated familial Alzheimer's disease","title_match":true,"year":2015},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/anti-amyloid-monoclonal-antibodies-for-alzheimer-s-disease-evidence-41003140","doi":"10.3390/jpm15090437","journal":"Journal of personalized medicine","n_participants":null,"pmid":"41003140","source_url":"https://pubmed.ncbi.nlm.nih.gov/41003140/","study_design":null,"title":"Anti-Amyloid Monoclonal Antibodies for Alzheimer's Disease: Evidence, ARIA Risk, and Precision Patient Selection","title_match":true,"year":2025},{"alzhub_score":71,"alzhub_url":"https://alzhub.org/study/lecanemab-in-clinical-practice-real-world-outcomes-in-early-alzheimer-40437535","doi":"10.1186/s13195-025-01763-1","journal":"Alzheimer's research & therapy","n_participants":31,"pmid":"40437535","source_url":"https://pubmed.ncbi.nlm.nih.gov/40437535/","study_design":"longitudinal study","title":"Lecanemab in clinical practice: real-world outcomes in early Alzheimer's disease","title_match":false,"year":2025},{"alzhub_score":48,"alzhub_url":"https://alzhub.org/study/benefits-and-risks-of-fda-approved-amyloid-targeting-antibodies-for-39306695","doi":"10.1002/alz.14199","journal":"Alzheimer's & dementia : the journal of the Alzheimer's Association","n_participants":null,"pmid":"39306695","source_url":"https://pubmed.ncbi.nlm.nih.gov/39306695/","study_design":null,"title":"Benefits and risks of FDA-approved amyloid-targeting antibodies for treatment of early Alzheimer's disease: Navigating clinician-patient engagement","title_match":false,"year":2024},{"alzhub_score":38,"alzhub_url":"https://alzhub.org/study/amyloid-related-imaging-abnormalities-in-an-aged-squirrel-monkey-with-28269776","doi":"10.3233/jad-160981","journal":"Journal of Alzheimer's disease : JAD","n_participants":null,"pmid":"28269776","source_url":"https://pubmed.ncbi.nlm.nih.gov/28269776/","study_design":null,"title":"Amyloid-Related Imaging Abnormalities in an Aged Squirrel Monkey with Cerebral Amyloid Angiopathy","title_match":true,"year":2017},{"alzhub_score":88,"alzhub_url":"https://alzhub.org/study/trailblazer-alz-4-a-phase-3-trial-comparing-donanemab-with-aducanumab-40390253","doi":"10.1002/alz.70293","journal":"Alzheimer's & dementia : the journal of the Alzheimer's Association","n_participants":148,"pmid":"40390253","source_url":"https://pubmed.ncbi.nlm.nih.gov/40390253/","study_design":"clinical trial","title":"TRAILBLAZER-ALZ 4: A phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer's disease","title_match":false,"year":2025},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/amyloid-related-imaging-abnormalities-in-the-era-of-anti-amyloid-beta-39109501","doi":"10.3348/kjr.2024.0105","journal":"Korean journal of radiology","n_participants":null,"pmid":"39109501","source_url":"https://pubmed.ncbi.nlm.nih.gov/39109501/","study_design":null,"title":"Amyloid-Related Imaging Abnormalities in the Era of Anti-Amyloid Beta Monoclonal Antibodies for Alzheimer's Disease: Recent Updates on Clinical and Imaging Features and MRI Monitoring","title_match":true,"year":2024},{"alzhub_score":83,"alzhub_url":"https://alzhub.org/study/results-from-the-long-term-extension-of-prime-a-randomized-phase-1b-38567735","doi":"10.1002/alz.13755","journal":"Alzheimer's & dementia : the journal of the Alzheimer's Association","n_participants":null,"pmid":"38567735","source_url":"https://pubmed.ncbi.nlm.nih.gov/38567735/","study_design":null,"title":"Results from the long-term extension of PRIME: A randomized Phase 1b trial of aducanumab","title_match":false,"year":2024},{"alzhub_score":66,"alzhub_url":"https://alzhub.org/study/prognostic-and-predictive-factors-in-early-alzheimer-s-disease-a-38405341","doi":"10.3233/adr-230045","journal":"Journal of Alzheimer's disease reports","n_participants":null,"pmid":"38405341","source_url":"https://pubmed.ncbi.nlm.nih.gov/38405341/","study_design":null,"title":"Prognostic and Predictive Factors in Early Alzheimer's Disease: A Systematic Review","title_match":false,"year":2024},{"alzhub_score":77,"alzhub_url":"https://alzhub.org/study/long-term-safety-and-efficacy-of-bapineuzumab-in-patients-with-mild-30129411","doi":"10.2174/1567205015666180821114813","journal":"Current Alzheimer research","n_participants":85,"pmid":"30129411","source_url":"https://pubmed.ncbi.nlm.nih.gov/30129411/","study_design":"clinical trial","title":"Long-Term Safety and Efficacy of Bapineuzumab in Patients with Mild-to-Moderate Alzheimer's Disease: A Phase 2, Open-Label Extension Study","title_match":false,"year":2018},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/a-combined-physiologically-based-pharmacokinetic-and-quantitative-36632701","doi":"10.1002/psp4.12912","journal":"CPT: pharmacometrics & systems pharmacology","n_participants":null,"pmid":"36632701","source_url":"https://pubmed.ncbi.nlm.nih.gov/36632701/","study_design":null,"title":"A combined physiologically-based pharmacokinetic and quantitative systems pharmacology model for modeling amyloid aggregation in Alzheimer's disease","title_match":false,"year":2023},{"alzhub_score":72,"alzhub_url":"https://alzhub.org/study/re-evaluation-of-the-efficacy-and-safety-of-anti-a-monoclonal-40308765","doi":"10.3389/fphar.2025.1599048","journal":"Frontiers in pharmacology","n_participants":null,"pmid":"40308765","source_url":"https://pubmed.ncbi.nlm.nih.gov/40308765/","study_design":"meta-analysis","title":"Re-evaluation of the efficacy and safety of anti-A\u03b2 monoclonal antibodies (lecanemab/donanemab) in the treatment of early Alzheimer's disease","title_match":false,"year":2025},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/safety-and-effectiveness-of-the-anti-amyloid-monoclonal-antibody-mab-40051090","doi":"10.1002/bcp.70021","journal":"British journal of clinical pharmacology","n_participants":null,"pmid":"40051090","source_url":"https://pubmed.ncbi.nlm.nih.gov/40051090/","study_design":"narrative review","title":"Safety and effectiveness of the anti-amyloid monoclonal antibody (mAb) drug lecanemab for early Alzheimer's disease: The pharmacovigilance perspective","title_match":false,"year":2025},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/lecanemab-appropriate-use-recommendations-by-korean-dementia-39512702","doi":"10.12779/dnd.2024.23.4.165","journal":"Dementia and neurocognitive disorders","n_participants":null,"pmid":"39512702","source_url":"https://pubmed.ncbi.nlm.nih.gov/39512702/","study_design":null,"title":"Lecanemab: Appropriate Use Recommendations by Korean Dementia Association","title_match":false,"year":2024},{"alzhub_score":53,"alzhub_url":"https://alzhub.org/study/ischemic-stroke-associated-with-amyloid-related-imaging-abnormalities-39215494","doi":"10.1002/alz.14223","journal":"Alzheimer's & dementia : the journal of the Alzheimer's Association","n_participants":null,"pmid":"39215494","source_url":"https://pubmed.ncbi.nlm.nih.gov/39215494/","study_design":null,"title":"Ischemic stroke associated with amyloid-related imaging abnormalities in a patient treated with lecanemab","title_match":true,"year":2024},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/amyloid-beta-oligomers-activate-death-receptors-and-mitochondria-38132159","doi":"10.3390/cells12242840","journal":"Cells","n_participants":null,"pmid":"38132159","source_url":"https://pubmed.ncbi.nlm.nih.gov/38132159/","study_design":null,"title":"Amyloid Beta Oligomers Activate Death Receptors and Mitochondria-Mediated Apoptotic Pathways in Cerebral Vascular Smooth Muscle Cells; Protective Effects of Carbonic Anhydrase Inhibitors","title_match":false,"year":2023},{"alzhub_score":67,"alzhub_url":"https://alzhub.org/study/application-of-meta-analysis-to-evaluate-relationships-among-aria-e-35320578","doi":"10.1007/s43441-022-00390-4","journal":"Therapeutic innovation & regulatory science","n_participants":null,"pmid":"35320578","source_url":"https://pubmed.ncbi.nlm.nih.gov/35320578/","study_design":"meta-analysis","title":"Application of Meta-analysis to Evaluate Relationships Among ARIA-E Rate, Amyloid Reduction Rate, and Clinical Cognitive Response in Amyloid Therapeutic Clinical Trials for Early Alzheimer's Disease","title_match":true,"year":2022},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/sar228810-an-antibody-for-protofibrillar-amyloid-peptide-designed-to-30486882","doi":"10.1186/s13195-018-0447-y","journal":"Alzheimer's research & therapy","n_participants":null,"pmid":"30486882","source_url":"https://pubmed.ncbi.nlm.nih.gov/30486882/","study_design":null,"title":"SAR228810: an antibody for protofibrillar amyloid \u03b2 peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA)","title_match":true,"year":2018},{"alzhub_score":55,"alzhub_url":"https://alzhub.org/study/population-pharmacokinetics-and-exposure-response-analyses-of-safety-39207112","doi":"10.1002/psp4.13224","journal":"CPT: pharmacometrics & systems pharmacology","n_participants":2641,"pmid":"39207112","source_url":"https://pubmed.ncbi.nlm.nih.gov/39207112/","study_design":null,"title":"Population pharmacokinetics and exposure-response analyses of safety (ARIA-E and isolated ARIA-H) of lecanemab in subjects with early Alzheimer's disease","title_match":true,"year":2024},{"alzhub_score":40,"alzhub_url":"https://alzhub.org/study/advances-in-amyloid-targeting-monoclonal-antibodies-for-alzheimer-s-37975226","doi":"10.1080/14737175.2023.2284305","journal":"Expert review of neurotherapeutics","n_participants":null,"pmid":"37975226","source_url":"https://pubmed.ncbi.nlm.nih.gov/37975226/","study_design":null,"title":"Advances in amyloid-targeting monoclonal antibodies for Alzheimer's disease: clinical and public health issues","title_match":false,"year":2023},{"alzhub_score":50,"alzhub_url":"https://alzhub.org/study/monoclonal-antibody-administration-in-an-academic-institution-and-40355750","doi":"10.1007/s00415-025-13142-9","journal":"Journal of neurology","n_participants":165,"pmid":"40355750","source_url":"https://pubmed.ncbi.nlm.nih.gov/40355750/","study_design":null,"title":"Monoclonal antibody administration in an academic institution and private neurological practice: a tale of two clinics","title_match":false,"year":2025},{"alzhub_score":83,"alzhub_url":"https://alzhub.org/study/the-efficacy-and-safety-of-anti-amyloid-monoclonal-antibody-versus-40316479","doi":"10.1016/j.tjpad.2025.100195","journal":"The journal of prevention of Alzheimer's disease","n_participants":8010,"pmid":"40316479","source_url":"https://pubmed.ncbi.nlm.nih.gov/40316479/","study_design":"randomized controlled trial","title":"The efficacy and safety of anti-amyloid monoclonal antibody versus acetylcholinesterase inhibitor with an in-depth analysis across genotypes and disease stages: a systematic review and meta-analysis","title_match":false,"year":2025},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/amyloid-related-imaging-abnormalities-aria-diagnosis-management-and-38939962","doi":"10.1002/acn3.52042","journal":"Annals of clinical and translational neurology","n_participants":null,"pmid":"38939962","source_url":"https://pubmed.ncbi.nlm.nih.gov/38939962/","study_design":null,"title":"Amyloid-related imaging abnormalities (ARIA): diagnosis, management, and care in the setting of amyloid-modifying therapy","title_match":true,"year":2024},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/disease-modeling-and-model-based-meta-analyses-to-define-a-new-35100444","doi":"10.1002/cpt.2535","journal":"Clinical pharmacology and therapeutics","n_participants":null,"pmid":"35100444","source_url":"https://pubmed.ncbi.nlm.nih.gov/35100444/","study_design":"open-label trial","title":"Disease Modeling and Model-Based Meta-Analyses to Define a New Direction for a Phase III Program of Gantenerumab in Alzheimer's Disease","title_match":false,"year":2022},{"alzhub_score":72,"alzhub_url":"https://alzhub.org/study/long-term-follow-up-of-patients-with-mild-to-moderate-alzheimer-s-29914022","doi":"10.3233/jad-171157","journal":"Journal of Alzheimer's disease : JAD","n_participants":1462,"pmid":"29914022","source_url":"https://pubmed.ncbi.nlm.nih.gov/29914022/","study_design":null,"title":"Long-Term Follow Up of Patients with Mild-to-Moderate Alzheimer's Disease Treated with Bapineuzumab in a Phase III, Open-Label, Extension Study","title_match":false,"year":2018},{"alzhub_score":72,"alzhub_url":"https://alzhub.org/study/the-efficacy-and-safety-of-lecanemab-10-mg-kg-biweekly-compared-to-a-38565747","doi":"10.1007/s10072-024-07477-w","journal":"Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","n_participants":null,"pmid":"38565747","source_url":"https://pubmed.ncbi.nlm.nih.gov/38565747/","study_design":"systematic review","title":"The efficacy and safety of lecanemab 10 mg/kg biweekly compared to a placebo in patients with Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials","title_match":false,"year":2024},{"alzhub_score":55,"alzhub_url":"https://alzhub.org/study/in-silico-exploration-of-amyloid-related-imaging-abnormalities-in-the-35676943","doi":"10.1002/trc2.12306","journal":"Alzheimer's & dementia (New York, N. Y.)","n_participants":112,"pmid":"35676943","source_url":"https://pubmed.ncbi.nlm.nih.gov/35676943/","study_design":"open-label trial","title":"In silico exploration of amyloid-related imaging abnormalities in the gantenerumab open-label extension trials using a semi-mechanistic model","title_match":true,"year":2022},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/recent-advances-in-antibody-therapy-for-alzheimer-s-disease-focus-on-40650049","doi":"10.3390/ijms26136271","journal":"International journal of molecular sciences","n_participants":null,"pmid":"40650049","source_url":"https://pubmed.ncbi.nlm.nih.gov/40650049/","study_design":null,"title":"Recent Advances in Antibody Therapy for Alzheimer's Disease: Focus on Bispecific Antibodies","title_match":false,"year":2025},{"alzhub_score":76,"alzhub_url":"https://alzhub.org/study/use-of-lecanemab-for-the-treatment-of-alzheimer-s-disease-a-38867460","doi":"10.1002/brb3.3592","journal":"Brain and behavior","n_participants":null,"pmid":"38867460","source_url":"https://pubmed.ncbi.nlm.nih.gov/38867460/","study_design":"meta-analysis","title":"Use of lecanemab for the treatment of Alzheimer's disease: A systematic review","title_match":false,"year":2024},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/lecanemab-a-second-in-class-therapy-for-the-management-of-early-38779110","doi":"10.24926/iip.v15i1.5787","journal":"Innovations in pharmacy","n_participants":null,"pmid":"38779110","source_url":"https://pubmed.ncbi.nlm.nih.gov/38779110/","study_design":null,"title":"Lecanemab: A Second in Class Therapy for the Management of Early Alzheimer's Disease","title_match":false,"year":2024},{"alzhub_score":64,"alzhub_url":"https://alzhub.org/study/amyloid-related-imaging-abnormalities-and-other-mri-findings-in-a-36281665","doi":"10.14283/jpad.2022.56","journal":"The journal of prevention of Alzheimer's disease","n_participants":1250,"pmid":"36281665","source_url":"https://pubmed.ncbi.nlm.nih.gov/36281665/","study_design":"cross-sectional","title":"Amyloid-Related Imaging Abnormalities and Other MRI Findings in a Cognitively Unimpaired Population With and Without Cerebral Amyloid","title_match":true,"year":2022},{"alzhub_score":40,"alzhub_url":"https://alzhub.org/study/vascular-considerations-for-amyloid-immunotherapy-36269539","doi":"10.1007/s11910-022-01235-1","journal":"Current neurology and neuroscience reports","n_participants":null,"pmid":"36269539","source_url":"https://pubmed.ncbi.nlm.nih.gov/36269539/","study_design":null,"title":"Vascular Considerations for Amyloid Immunotherapy","title_match":false,"year":2022},{"alzhub_score":40,"alzhub_url":"https://alzhub.org/study/aducanumab-for-alzheimer-s-disease-summarized-data-from-emerge-engage-35879846","doi":"10.4140/tcp.n.2022.329","journal":"The Senior care pharmacist","n_participants":null,"pmid":"35879846","source_url":"https://pubmed.ncbi.nlm.nih.gov/35879846/","study_design":"clinical trial","title":"Aducanumab for Alzheimer's Disease: Summarized Data From EMERGE, ENGAGE, and PRIME Studies","title_match":false,"year":2022},{"alzhub_score":74,"alzhub_url":"https://alzhub.org/study/lecanemab-treatment-for-alzheimer-s-disease-of-varying-severities-and-41070709","doi":"10.1002/alz.70750","journal":"Alzheimer's & dementia : the journal of the Alzheimer's Association","n_participants":68,"pmid":"41070709","source_url":"https://pubmed.ncbi.nlm.nih.gov/41070709/","study_design":"cohort study","title":"Lecanemab treatment for Alzheimer's Disease of varying severities and associated plasma biomarkers monitoring: A multi-center real-world study in China","title_match":false,"year":2025},{"alzhub_score":72,"alzhub_url":"https://alzhub.org/study/a-systematic-review-of-the-efficacy-and-safety-of-anti-amyloid-40621323","doi":"10.7759/cureus.85377","journal":"Cureus","n_participants":null,"pmid":"40621323","source_url":"https://pubmed.ncbi.nlm.nih.gov/40621323/","study_design":"systematic review","title":"A Systematic Review of the Efficacy and Safety of Anti-amyloid Monoclonal Antibodies in Alzheimer's Disease","title_match":false,"year":2025},{"alzhub_score":50,"alzhub_url":"https://alzhub.org/study/intracerebral-hemorrhage-following-mild-aria-h-in-an-apoe-2-carrier-39702440","doi":"10.1186/s13195-024-01640-3","journal":"Alzheimer's research & therapy","n_participants":null,"pmid":"39702440","source_url":"https://pubmed.ncbi.nlm.nih.gov/39702440/","study_design":null,"title":"Intracerebral hemorrhage following mild ARIA-H in an APOE \u03b52 carrier receiving lecanemab","title_match":true,"year":2024},{"alzhub_score":79,"alzhub_url":"https://alzhub.org/study/greater-white-matter-hyperintensity-volume-is-associated-with-the-39044495","doi":"10.14283/jpad.2024.139","journal":"The journal of prevention of Alzheimer's disease","n_participants":null,"pmid":"39044495","source_url":"https://pubmed.ncbi.nlm.nih.gov/39044495/","study_design":"longitudinal study","title":"Greater White Matter Hyperintensity Volume Is Associated with the Number of Microhemorrhages in Preclinical Alzheimer's Disease","title_match":false,"year":2024},{"alzhub_score":47,"alzhub_url":"https://alzhub.org/study/initial-experiences-with-amyloid-related-imaging-abnormalities-in-37874098","doi":"10.14283/jpad.2023.96","journal":"The journal of prevention of Alzheimer's disease","n_participants":24,"pmid":"37874098","source_url":"https://pubmed.ncbi.nlm.nih.gov/37874098/","study_design":null,"title":"Initial Experiences with Amyloid-Related Imaging Abnormalities in Patients Receiving Aducanumab Following Accelerated Approval","title_match":true,"year":2023},{"alzhub_score":52,"alzhub_url":"https://alzhub.org/study/therapeutic-preference-for-alzheimer-s-disease-treatments-a-discrete-36964606","doi":"10.1186/s13195-023-01207-8","journal":"Alzheimer's research & therapy","n_participants":137,"pmid":"36964606","source_url":"https://pubmed.ncbi.nlm.nih.gov/36964606/","study_design":null,"title":"Therapeutic preference for Alzheimer's disease treatments: a discrete choice experiment with caregivers and neurologists","title_match":false,"year":2023},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/new-developments-of-clinical-trial-in-immunotherapy-for-alzheimer-s-25860060","doi":"10.2174/138920101606150407112319","journal":"Current pharmaceutical biotechnology","n_participants":null,"pmid":"25860060","source_url":"https://pubmed.ncbi.nlm.nih.gov/25860060/","study_design":"clinical trial","title":"New developments of clinical trial in immunotherapy for Alzheimer's disease","title_match":false,"year":2015},{"alzhub_score":50,"alzhub_url":"https://alzhub.org/study/a-real-world-pharmacovigilance-study-of-adverse-drug-reactions-40290431","doi":"10.3389/fphar.2025.1561020","journal":"Frontiers in pharmacology","n_participants":null,"pmid":"40290431","source_url":"https://pubmed.ncbi.nlm.nih.gov/40290431/","study_design":null,"title":"A real-world pharmacovigilance study of adverse drug reactions associated with lecanemab and aducanumab based on WHO-VigiAccess and FAERS databases","title_match":false,"year":2025},{"alzhub_score":53,"alzhub_url":"https://alzhub.org/study/a-real-world-disproportionality-analysis-of-fda-adverse-event-40242445","doi":"10.3389/fphar.2025.1559447","journal":"Frontiers in pharmacology","n_participants":811,"pmid":"40242445","source_url":"https://pubmed.ncbi.nlm.nih.gov/40242445/","study_design":"clinical trial","title":"A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for lecanemab","title_match":false,"year":2025},{"alzhub_score":48,"alzhub_url":"https://alzhub.org/study/quantitative-systems-pharmacology-based-exploration-of-relevant-anti-38774587","doi":"10.1002/trc2.12474","journal":"Alzheimer's & dementia (New York, N. Y.)","n_participants":null,"pmid":"38774587","source_url":"https://pubmed.ncbi.nlm.nih.gov/38774587/","study_design":null,"title":"Quantitative systems pharmacology-based exploration of relevant anti-amyloid therapy challenges in clinical practice","title_match":false,"year":2024},{"alzhub_score":47,"alzhub_url":"https://alzhub.org/study/anti-amyloid-therapies-and-the-transformation-of-alzheimer-s-care-41732200","doi":"10.1016/j.lanepe.2026.101609","journal":"The Lancet regional health. Europe","n_participants":null,"pmid":"41732200","source_url":"https://pubmed.ncbi.nlm.nih.gov/41732200/","study_design":null,"title":"Anti-amyloid therapies and the transformation of Alzheimer's care pathways: early lessons from the frontline","title_match":false,"year":2026},{"alzhub_score":50,"alzhub_url":"https://alzhub.org/study/two-cases-of-amyloid-related-imaging-abnormalities-aria-following-40624486","doi":"10.1186/s12883-025-04302-5","journal":"BMC neurology","n_participants":null,"pmid":"40624486","source_url":"https://pubmed.ncbi.nlm.nih.gov/40624486/","study_design":null,"title":"Two cases of Amyloid-Related Imaging Abnormalities (ARIA) following lecanemab treatment for alzheimer's disease and a literature review","title_match":true,"year":2025},{"alzhub_score":59,"alzhub_url":"https://alzhub.org/study/comparison-of-safety-of-lecanemab-and-aducanumab-a-real-world-40520157","doi":"10.3389/fphar.2025.1593989","journal":"Frontiers in pharmacology","n_participants":1409,"pmid":"40520157","source_url":"https://pubmed.ncbi.nlm.nih.gov/40520157/","study_design":null,"title":"Comparison of safety of lecanemab and aducanumab: a real-world disproportionality analysis using the FDA adverse event reporting system","title_match":false,"year":2025},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/use-of-artificial-intelligence-in-imaging-dementia-39682713","doi":"10.3390/cells13231965","journal":"Cells","n_participants":null,"pmid":"39682713","source_url":"https://pubmed.ncbi.nlm.nih.gov/39682713/","study_design":null,"title":"Use of Artificial Intelligence in Imaging Dementia","title_match":false,"year":2024},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/more-failure-with-solanezumab-this-time-in-preclinical-alzheimer-s-38414336","doi":"10.1080/14712598.2024.2325551","journal":"Expert opinion on biological therapy","n_participants":null,"pmid":"38414336","source_url":"https://pubmed.ncbi.nlm.nih.gov/38414336/","study_design":"clinical trial","title":"More failure with solanezumab - this time in preclinical Alzheimer's disease","title_match":false,"year":2024},{"alzhub_score":53,"alzhub_url":"https://alzhub.org/study/validation-of-3-and-5-point-severity-scales-to-assess-aria-e-38026755","doi":"10.1002/dad2.12503","journal":"Alzheimer's & dementia (Amsterdam, Netherlands)","n_participants":75,"pmid":"38026755","source_url":"https://pubmed.ncbi.nlm.nih.gov/38026755/","study_design":null,"title":"Validation of 3- and 5-point severity scales to assess ARIA-E","title_match":true,"year":2023},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/alzheimer-s-disease-and-epilepsy-shared-neuropathology-guides-current-37936917","doi":"10.3389/fneur.2023.1241339","journal":"Frontiers in neurology","n_participants":null,"pmid":"37936917","source_url":"https://pubmed.ncbi.nlm.nih.gov/37936917/","study_design":null,"title":"Alzheimer's disease and epilepsy: shared neuropathology guides current and future treatment strategies","title_match":false,"year":2023},{"alzhub_score":47,"alzhub_url":"https://alzhub.org/study/targeting-immunometabolic-pathways-for-combination-therapy-in-37786483","doi":"10.1002/trc2.12423","journal":"Alzheimer's & dementia (New York, N. Y.)","n_participants":null,"pmid":"37786483","source_url":"https://pubmed.ncbi.nlm.nih.gov/37786483/","study_design":null,"title":"Targeting immunometabolic pathways for combination therapy in Alzheimer's disease","title_match":false,"year":2023},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/data-driven-modeling-of-amyloid-targeted-antibodies-for-alzheimer-s-41271757","doi":"10.1038/s41540-025-00610-1","journal":"NPJ systems biology and applications","n_participants":null,"pmid":"41271757","source_url":"https://pubmed.ncbi.nlm.nih.gov/41271757/","study_design":null,"title":"Data-driven modeling of amyloid-\u03b2 targeted antibodies for Alzheimer's disease","title_match":false,"year":2025},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/review-of-anti-amyloid-beta-a-monoclonal-antibodies-for-the-treatment-40940304","doi":"10.1080/17512433.2025.2556122","journal":"Expert review of clinical pharmacology","n_participants":null,"pmid":"40940304","source_url":"https://pubmed.ncbi.nlm.nih.gov/40940304/","study_design":null,"title":"Review of anti-amyloid-beta (A\u03b2) monoclonal antibodies for the treatment of Alzheimer's disease","title_match":false,"year":2025},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/mouse-models-of-anti-a-immunotherapies-40361247","doi":"10.1186/s13024-025-00836-x","journal":"Molecular neurodegeneration","n_participants":null,"pmid":"40361247","source_url":"https://pubmed.ncbi.nlm.nih.gov/40361247/","study_design":null,"title":"Mouse models of Anti-A\u03b2 immunotherapies","title_match":false,"year":2025},{"alzhub_score":84,"alzhub_url":"https://alzhub.org/study/japanese-subgroup-analyses-from-emerge-and-engage-phase-3-clinical-39350371","doi":"10.14283/jpad.2024.106","journal":"The journal of prevention of Alzheimer's disease","n_participants":121,"pmid":"39350371","source_url":"https://pubmed.ncbi.nlm.nih.gov/39350371/","study_design":"clinical trial","title":"Japanese Subgroup Analyses from EMERGE and ENGAGE, Phase 3 Clinical Trials of Aducanumab in Patients with Early Alzheimer's Disease","title_match":false,"year":2024},{"alzhub_score":40,"alzhub_url":"https://alzhub.org/study/mri-in-the-new-era-of-antiamyloid-mabs-for-the-treatment-of-alzheimer-37382144","doi":"10.1097/wco.0000000000001177","journal":"Current opinion in neurology","n_participants":null,"pmid":"37382144","source_url":"https://pubmed.ncbi.nlm.nih.gov/37382144/","study_design":null,"title":"MRI in the new era of antiamyloid mAbs for the treatment of Alzheimer's disease","title_match":false,"year":2023},{"alzhub_score":69,"alzhub_url":"https://alzhub.org/study/the-value-of-subtraction-mri-in-detection-of-amyloid-related-imaging-28956123","doi":"10.1007/s00330-017-5022-6","journal":"European radiology","n_participants":75,"pmid":"28956123","source_url":"https://pubmed.ncbi.nlm.nih.gov/28956123/","study_design":null,"title":"The value of subtraction MRI in detection of amyloid-related imaging abnormalities with oedema or effusion in Alzheimer's patients: An interobserver study","title_match":true,"year":2018},{"alzhub_score":79,"alzhub_url":"https://alzhub.org/study/efficacy-and-apoe-4-stratified-risk-of-donanemab-in-alzheimer-s-40692324","doi":"10.1177/13872877251361044","journal":"Journal of Alzheimer's disease : JAD","n_participants":2054,"pmid":"40692324","source_url":"https://pubmed.ncbi.nlm.nih.gov/40692324/","study_design":"systematic review","title":"Efficacy and APOE \u03b54-stratified risk of donanemab in Alzheimer's disease: A systematic review and meta-analysis of randomized clinical trials","title_match":false,"year":2025},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/pet-ct-mri-in-clinical-trials-of-alzheimer-s-disease-39422954","doi":"10.3233/jad-240206","journal":"Journal of Alzheimer's disease : JAD","n_participants":null,"pmid":"39422954","source_url":"https://pubmed.ncbi.nlm.nih.gov/39422954/","study_design":null,"title":"PET/CT/MRI in Clinical Trials of Alzheimer's Disease","title_match":false,"year":2024},{"alzhub_score":66,"alzhub_url":"https://alzhub.org/study/apoe-4-allele-s-associated-adverse-events-reported-from-placebo-arm-39081988","doi":"10.3389/frdem.2023.1320329","journal":"Frontiers in dementia","n_participants":6313,"pmid":"39081988","source_url":"https://pubmed.ncbi.nlm.nih.gov/39081988/","study_design":null,"title":"APOE -\u03b54 allele[s]-associated adverse events reported from placebo arm in clinical trials for Alzheimer's disease: implications for anti-amyloid beta therapy","title_match":false,"year":2023},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/recalibrating-the-risk-benefit-profiles-of-lecanemab-and-donanemab-38701151","doi":"10.3233/jad-240171","journal":"Journal of Alzheimer's disease : JAD","n_participants":null,"pmid":"38701151","source_url":"https://pubmed.ncbi.nlm.nih.gov/38701151/","study_design":null,"title":"Recalibrating the Risk-Benefit Profiles of Lecanemab and Donanemab: Scales, Immunoreactivity, and Changes in Amyloid-\u03b242","title_match":false,"year":2024},{"alzhub_score":47,"alzhub_url":"https://alzhub.org/study/fda-approved-passive-immunization-treatments-against-a-in-alzheimer-s-41596530","doi":"10.3390/ijms27020883","journal":"International journal of molecular sciences","n_participants":null,"pmid":"41596530","source_url":"https://pubmed.ncbi.nlm.nih.gov/41596530/","study_design":null,"title":"FDA-Approved Passive Immunization Treatments Against A\u03b2 in Alzheimer's Disease: Where Are We Now?","title_match":false,"year":2026},{"alzhub_score":81,"alzhub_url":"https://alzhub.org/study/influence-of-patient-characteristics-on-efficacy-and-safety-of-anti-41352683","doi":"10.1016/j.arr.2025.102981","journal":"Ageing research reviews","n_participants":5633,"pmid":"41352683","source_url":"https://pubmed.ncbi.nlm.nih.gov/41352683/","study_design":"systematic review","title":"Influence of patient characteristics on efficacy and safety of anti-amyloid monoclonal antibodies in Alzheimer's disease: A systematic review and meta-analysis","title_match":false,"year":2026},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/advances-of-therapeutic-strategies-for-alzheimer-s-disease-41107537","doi":"10.1007/s00415-025-13456-8","journal":"Journal of neurology","n_participants":null,"pmid":"41107537","source_url":"https://pubmed.ncbi.nlm.nih.gov/41107537/","study_design":null,"title":"Advances of therapeutic strategies for Alzheimer's disease","title_match":false,"year":2025},{"alzhub_score":89,"alzhub_url":"https://alzhub.org/study/safety-tolerability-immunogenicity-and-efficacy-of-abvac40-active-41058018","doi":"10.1002/alz.70776","journal":"Alzheimer's & dementia : the journal of the Alzheimer's Association","n_participants":124,"pmid":"41058018","source_url":"https://pubmed.ncbi.nlm.nih.gov/41058018/","study_design":"clinical trial","title":"Safety, tolerability, immunogenicity, and efficacy of ABvac40 active immunotherapy against A\u03b240 in patients with mild cognitive impairment or very mild Alzheimer's disease: A randomized, double-blind, placebo-controlled phase 2 study","title_match":false,"year":2025},{"alzhub_score":52,"alzhub_url":"https://alzhub.org/study/predicting-severity-of-cerebral-amyloid-angiopathy-neuropathology-a-41057989","doi":"10.1002/alz.70057","journal":"Alzheimer's & dementia : the journal of the Alzheimer's Association","n_participants":null,"pmid":"41057989","source_url":"https://pubmed.ncbi.nlm.nih.gov/41057989/","study_design":null,"title":"Predicting severity of cerebral amyloid angiopathy neuropathology: A modeling approach using NACC and ROSMAP data","title_match":false,"year":2025},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/amyloid-related-imaging-abnormalities-aria-in-the-context-of-41042497","doi":"10.1007/s40266-025-01253-x","journal":"Drugs & aging","n_participants":null,"pmid":"41042497","source_url":"https://pubmed.ncbi.nlm.nih.gov/41042497/","study_design":null,"title":"Amyloid-related Imaging Abnormalities (ARIA) in the Context of Alzheimer's Disease and Amyloid-targeting Therapies: An Introduction for Advanced Practice Providers","title_match":true,"year":2025},{"alzhub_score":57,"alzhub_url":"https://alzhub.org/study/a-novel-biochemical-analysis-for-apoe4-quantification-in-plasma-and-40671162","doi":"10.1186/s13195-025-01811-w","journal":"Alzheimer's research & therapy","n_participants":160,"pmid":"40671162","source_url":"https://pubmed.ncbi.nlm.nih.gov/40671162/","study_design":null,"title":"A novel biochemical analysis for ApoE4 quantification in plasma and discrimination of homozygous and heterozygous APOE \u03b54 carriers","title_match":false,"year":2025},{"alzhub_score":84,"alzhub_url":"https://alzhub.org/study/oral-pri-002-treatment-in-patients-with-mci-or-mild-ad-a-randomized-40324978","doi":"10.1038/s41467-025-59295-z","journal":"Nature communications","n_participants":20,"pmid":"40324978","source_url":"https://pubmed.ncbi.nlm.nih.gov/40324978/","study_design":null,"title":"Oral PRI-002 treatment in patients with MCI or mild AD: a randomized, double-blind phase 1b trial","title_match":false,"year":2025},{"alzhub_score":66,"alzhub_url":"https://alzhub.org/study/exploring-the-efficacy-and-safety-of-lecanemab-in-the-management-of-40232258","doi":"10.1177/13872877251331640","journal":"Journal of Alzheimer's disease : JAD","n_participants":null,"pmid":"40232258","source_url":"https://pubmed.ncbi.nlm.nih.gov/40232258/","study_design":"clinical trial","title":"Exploring the efficacy and safety of lecanemab in the management of early Alzheimer's disease: A systematic review of clinical evidence","title_match":false,"year":2025},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/profiling-aducanumab-as-a-treatment-option-for-alzheimer-s-disease-an-39291991","doi":"10.1080/14737175.2024.2402058","journal":"Expert review of neurotherapeutics","n_participants":null,"pmid":"39291991","source_url":"https://pubmed.ncbi.nlm.nih.gov/39291991/","study_design":null,"title":"Profiling aducanumab as a treatment option for Alzheimer's disease: an overview of efficacy, safety and tolerability","title_match":false,"year":2024},{"alzhub_score":84,"alzhub_url":"https://alzhub.org/study/gantenerumab-for-early-alzheimer-s-disease-a-systematic-review-and-38879828","doi":"10.1080/14737175.2024.2367016","journal":"Expert review of neurotherapeutics","n_participants":2848,"pmid":"38879828","source_url":"https://pubmed.ncbi.nlm.nih.gov/38879828/","study_design":"meta-analysis","title":"Gantenerumab for early Alzheimer's disease: a systematic review and meta-analysis","title_match":false,"year":2024},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/anti-amyloid-monoclonal-antibody-therapies-in-alzheimer-s-disease-a-41077117","doi":"10.1016/j.neuroscience.2025.10.011","journal":"Neuroscience","n_participants":null,"pmid":"41077117","source_url":"https://pubmed.ncbi.nlm.nih.gov/41077117/","study_design":null,"title":"Anti-amyloid monoclonal antibody therapies in Alzheimer's disease - a scoping review","title_match":false,"year":2025},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/practical-brain-mri-guidelines-for-anti-a-antibody-treatment-in-early-40266549","doi":"10.1007/s11604-025-01773-x","journal":"Japanese journal of radiology","n_participants":null,"pmid":"40266549","source_url":"https://pubmed.ncbi.nlm.nih.gov/40266549/","study_design":null,"title":"Practical brain MRI guidelines for anti-A\u03b2 antibody treatment in early symptomatic Alzheimer's disease","title_match":false,"year":2025},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/cerebral-amyloid-angiopathy-clinical-presentation-sequelae-and-40149580","doi":"10.3390/biomedicines13030603","journal":"Biomedicines","n_participants":null,"pmid":"40149580","source_url":"https://pubmed.ncbi.nlm.nih.gov/40149580/","study_design":null,"title":"Cerebral Amyloid Angiopathy: Clinical Presentation, Sequelae and Neuroimaging Features-An Update","title_match":false,"year":2025},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/anti-amyloid-treatments-in-alzheimer-s-disease-elegance-evidence-and-39698778","doi":"10.17219/acem/198674","journal":"Advances in clinical and experimental medicine : official organ Wroclaw Medical University","n_participants":null,"pmid":"39698778","source_url":"https://pubmed.ncbi.nlm.nih.gov/39698778/","study_design":null,"title":"Anti-amyloid treatments in Alzheimer's disease: elegance, evidence and ethics","title_match":false,"year":2024},{"alzhub_score":77,"alzhub_url":"https://alzhub.org/study/long-term-safety-of-gantenerumab-in-participants-with-alzheimer-s-39177596","doi":"10.3233/jad-240221","journal":"Journal of Alzheimer's disease : JAD","n_participants":225,"pmid":"39177596","source_url":"https://pubmed.ncbi.nlm.nih.gov/39177596/","study_design":"open-label trial","title":"Long-Term Safety of Gantenerumab in Participants with Alzheimer's Disease: A Phase III, Double-Blind, and Open-Label Extension Study (Marguerite RoAD)","title_match":false,"year":2024},{"alzhub_score":50,"alzhub_url":"https://alzhub.org/study/the-black-book-of-psychotropic-dosing-and-monitoring-38993656","doi":"10.64719/pb.4493","journal":"Psychopharmacology bulletin","n_participants":407,"pmid":"38993656","source_url":"https://pubmed.ncbi.nlm.nih.gov/38993656/","study_design":"clinical trial","title":"The Black Book of Psychotropic Dosing and Monitoring","title_match":false,"year":2024},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/imaging-of-amyloid-related-imaging-abnormalities-aria-37995736","doi":"10.1055/a-2185-8472","journal":"RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin","n_participants":null,"pmid":"37995736","source_url":"https://pubmed.ncbi.nlm.nih.gov/37995736/","study_design":null,"title":"Imaging of Amyloid-Related Imaging Abnormalities (ARIA)","title_match":true,"year":2024},{"alzhub_score":47,"alzhub_url":"https://alzhub.org/study/amyloid-related-imaging-abnormalities-aria-in-alzheimer-s-disease-41904593","doi":"10.1186/s13195-026-02022-7","journal":"Alzheimer's research & therapy","n_participants":null,"pmid":"41904593","source_url":"https://pubmed.ncbi.nlm.nih.gov/41904593/","study_design":null,"title":"Amyloid-related imaging abnormalities (ARIA) in Alzheimer's disease: from pathophysiology to individualized risk assessment","title_match":true,"year":2026},{"alzhub_score":47,"alzhub_url":"https://alzhub.org/study/balancing-benefit-and-risk-in-early-alzheimer-s-disease-the-european-41852829","doi":"10.1016/j.lanepe.2026.101644","journal":"The Lancet regional health. Europe","n_participants":null,"pmid":"41852829","source_url":"https://pubmed.ncbi.nlm.nih.gov/41852829/","study_design":null,"title":"Balancing benefit and risk in early Alzheimer's disease: the European Medicines Agency (EMA) assessment of lecanemab and donanemab","title_match":false,"year":2026},{"alzhub_score":59,"alzhub_url":"https://alzhub.org/study/real-world-experience-with-baseline-characteristics-and-safety-of-41396015","doi":"10.1177/13872877251406619","journal":"Journal of Alzheimer's disease : JAD","n_participants":190,"pmid":"41396015","source_url":"https://pubmed.ncbi.nlm.nih.gov/41396015/","study_design":null,"title":"Real-world experience with baseline characteristics and safety of lecanemab for Alzheimer's disease in Eastern China","title_match":false,"year":2026},{"alzhub_score":72,"alzhub_url":"https://alzhub.org/study/higher-phosphorylated-tau-levels-predict-cognitive-decline-and-41276859","doi":"10.1186/s13195-025-01912-6","journal":"Alzheimer's research & therapy","n_participants":234,"pmid":"41276859","source_url":"https://pubmed.ncbi.nlm.nih.gov/41276859/","study_design":"longitudinal study","title":"Higher phosphorylated tau levels predict cognitive decline and amyloid-related imaging abnormalities during lecanemab treatment: clinical practice data","title_match":true,"year":2025},{"alzhub_score":56,"alzhub_url":"https://alzhub.org/study/effectiveness-safety-and-biomarker-dynamics-of-lecanemab-in-chinese-41823189","doi":"10.1002/alz.71231","journal":"Alzheimer's & dementia : the journal of the Alzheimer's Association","n_participants":null,"pmid":"41823189","source_url":"https://pubmed.ncbi.nlm.nih.gov/41823189/","study_design":null,"title":"Effectiveness, safety, and biomarker dynamics of lecanemab in Chinese Alzheimer's disease population: a multicenter real-world study","title_match":false,"year":2026},{"alzhub_score":55,"alzhub_url":"https://alzhub.org/study/evaluation-of-plasma-neurofilament-and-glial-fibrillary-acidic-42824090","doi":"10.1002/dad2.70446","journal":"Alzheimer's & dementia (Amsterdam, Netherlands)","n_participants":15,"pmid":"42824090","source_url":"https://pubmed.ncbi.nlm.nih.gov/42824090/","study_design":null,"title":"Evaluation of plasma neurofilament and glial fibrillary acidic protein to predict or detect amyloid related imaging abnormalities","title_match":false,"year":2026},{"alzhub_score":66,"alzhub_url":"https://alzhub.org/study/real-world-implementation-of-lecanemab-and-donanemab-in-an-italian-41857623","doi":"10.1186/s13195-026-02015-6","journal":"Alzheimer's research & therapy","n_participants":null,"pmid":"41857623","source_url":"https://pubmed.ncbi.nlm.nih.gov/41857623/","study_design":"cohort study","title":"Real-world implementation of lecanemab and donanemab in an Italian memory center: a 1-year experience","title_match":false,"year":2026},{"alzhub_score":57,"alzhub_url":"https://alzhub.org/study/preclinical-in-vivo-longitudinal-assessment-of-kg207-m-as-a-disease-34378436","doi":"10.1177/0271678x211035625","journal":"Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism","n_participants":null,"pmid":"34378436","source_url":"https://pubmed.ncbi.nlm.nih.gov/34378436/","study_design":"longitudinal study","title":"Preclinical in vivo longitudinal assessment of KG207-M as a disease-modifying Alzheimer's disease therapeutic","title_match":false,"year":2022},{"alzhub_score":80,"alzhub_url":"https://alzhub.org/study/donanemab-ly3002813-phase-1b-study-in-alzheimer-s-disease-rapid-and-34585215","doi":"10.14283/jpad.2021.56","journal":"The journal of prevention of Alzheimer's disease","n_participants":18,"pmid":"34585215","source_url":"https://pubmed.ncbi.nlm.nih.gov/34585215/","study_design":null,"title":"Donanemab (LY3002813) Phase 1b Study in Alzheimer's Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging","title_match":false,"year":2021},{"alzhub_score":61,"alzhub_url":"https://alzhub.org/study/eligibility-for-lecanemab-and-donanemab-in-korea-under-appropriate-41225766","doi":"10.1002/alz.70875","journal":"Alzheimer's & dementia : the journal of the Alzheimer's Association","n_participants":2726,"pmid":"41225766","source_url":"https://pubmed.ncbi.nlm.nih.gov/41225766/","study_design":null,"title":"Eligibility for lecanemab and donanemab in Korea under Appropriate Use Recommendations","title_match":false,"year":2025},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/treatment-of-alzheimer-disease-39620846","doi":"10.1212/con.0000000000001503","journal":"Continuum (Minneapolis, Minn.)","n_participants":null,"pmid":"39620846","source_url":"https://pubmed.ncbi.nlm.nih.gov/39620846/","study_design":null,"title":"Treatment of Alzheimer Disease","title_match":false,"year":2024},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/lecanemab-appropriate-use-recommendations-for-clinical-practice-in-41390238","doi":"10.1136/jnnp-2025-336597","journal":"Journal of neurology, neurosurgery, and psychiatry","n_participants":null,"pmid":"41390238","source_url":"https://pubmed.ncbi.nlm.nih.gov/41390238/","study_design":null,"title":"Lecanemab appropriate use recommendations for clinical practice in the UK","title_match":false,"year":2026},{"alzhub_score":70,"alzhub_url":"https://alzhub.org/study/aducanumab-for-the-treatment-of-alzheimer-s-disease-a-systematic-36775284","doi":"10.1111/psyg.12944","journal":"Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society","n_participants":null,"pmid":"36775284","source_url":"https://pubmed.ncbi.nlm.nih.gov/36775284/","study_design":"meta-analysis","title":"Aducanumab for the treatment of Alzheimer's disease: a systematic review","title_match":false,"year":2023},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/maximizing-the-benefit-and-managing-the-risk-of-anti-amyloid-40118715","doi":"10.1016/j.neurot.2025.e00570","journal":"Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics","n_participants":null,"pmid":"40118715","source_url":"https://pubmed.ncbi.nlm.nih.gov/40118715/","study_design":null,"title":"Maximizing the benefit and managing the risk of anti-amyloid monoclonal antibody therapy for Alzheimer's disease: Strategies and research directions","title_match":false,"year":2025},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/imaging-spectrum-of-amyloid-related-imaging-abnormalities-associated-38249159","doi":"10.3389/fradi.2023.1305390","journal":"Frontiers in radiology","n_participants":null,"pmid":"38249159","source_url":"https://pubmed.ncbi.nlm.nih.gov/38249159/","study_design":null,"title":"Imaging spectrum of amyloid-related imaging abnormalities associated with aducanumab immunotherapy","title_match":true,"year":2023},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/safety-of-switching-from-lecanemab-to-donanemab-in-20-consecutive-40708311","doi":"10.1177/13872877251361051","journal":"Journal of Alzheimer's disease : JAD","n_participants":null,"pmid":"40708311","source_url":"https://pubmed.ncbi.nlm.nih.gov/40708311/","study_design":null,"title":"Safety of switching from lecanemab to donanemab in 20 consecutive patients with Alzheimer's disease","title_match":false,"year":2025},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/donanemab-another-anti-alzheimer-s-drug-with-risk-and-uncertain-38830549","doi":"10.1016/j.arr.2024.102348","journal":"Ageing research reviews","n_participants":null,"pmid":"38830549","source_url":"https://pubmed.ncbi.nlm.nih.gov/38830549/","study_design":null,"title":"Donanemab, another anti-Alzheimer's drug with risk and uncertain benefit","title_match":false,"year":2024},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/anti-amyloid-antibody-therapies-for-alzheimer-s-disease-38932758","doi":"10.1007/s13139-024-00848-3","journal":"Nuclear medicine and molecular imaging","n_participants":null,"pmid":"38932758","source_url":"https://pubmed.ncbi.nlm.nih.gov/38932758/","study_design":"clinical trial","title":"Anti-amyloid Antibody Therapies for Alzheimer's Disease","title_match":false,"year":2024},{"alzhub_score":83,"alzhub_url":"https://alzhub.org/study/safety-and-efficacy-of-long-term-gantenerumab-treatment-in-dominantly-40120616","doi":"10.1016/s1474-4422(25)00024-9","journal":"The Lancet. Neurology","n_participants":53,"pmid":"40120616","source_url":"https://pubmed.ncbi.nlm.nih.gov/40120616/","study_design":"clinical trial","title":"Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial","title_match":false,"year":2025},{"alzhub_score":46,"alzhub_url":"https://alzhub.org/study/identifying-genetic-risk-for-amyloid-related-imaging-abnormalities-38165303","doi":"10.1212/wnl.0000000000208096","journal":"Neurology","n_participants":null,"pmid":"38165303","source_url":"https://pubmed.ncbi.nlm.nih.gov/38165303/","study_design":null,"title":"Identifying Genetic Risk for Amyloid-Related Imaging Abnormalities","title_match":true,"year":2024},{"alzhub_score":46,"alzhub_url":"https://alzhub.org/study/neuropathology-of-anti-amyloid-immunotherapy-a-case-report-37125554","doi":"10.3233/jad-221305","journal":"Journal of Alzheimer's disease : JAD","n_participants":null,"pmid":"37125554","source_url":"https://pubmed.ncbi.nlm.nih.gov/37125554/","study_design":null,"title":"Neuropathology of Anti-Amyloid-\u03b2 Immunotherapy: A Case Report","title_match":false,"year":2023},{"alzhub_score":89,"alzhub_url":"https://alzhub.org/study/gantenerumab-for-early-alzheimer-s-disease-an-updated-systematic-42605139","doi":"10.1002/brb3.71643","journal":"Brain and behavior","n_participants":3103,"pmid":"42605139","source_url":"https://pubmed.ncbi.nlm.nih.gov/42605139/","study_design":"systematic review","title":"Gantenerumab for Early Alzheimer's Disease: An Updated Systematic Review and Meta-Analysis","title_match":false,"year":2026},{"alzhub_score":46,"alzhub_url":"https://alzhub.org/study/how-donanemab-data-address-the-coverage-with-evidence-development-38323738","doi":"10.1002/alz.13700","journal":"Alzheimer's & dementia : the journal of the Alzheimer's Association","n_participants":null,"pmid":"38323738","source_url":"https://pubmed.ncbi.nlm.nih.gov/38323738/","study_design":null,"title":"How donanemab data address the coverage with evidence development questions","title_match":false,"year":2024},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/pharmacokinetic-evaluation-of-donanemab-for-the-treatment-of-38758223","doi":"10.1080/17425255.2024.2357637","journal":"Expert opinion on drug metabolism & toxicology","n_participants":null,"pmid":"38758223","source_url":"https://pubmed.ncbi.nlm.nih.gov/38758223/","study_design":null,"title":"Pharmacokinetic evaluation of donanemab for the treatment of Alzheimer's","title_match":false,"year":2024},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/lecanemab-more-questions-than-answers-38095822","doi":"10.1007/s40261-023-01331-1","journal":"Clinical drug investigation","n_participants":null,"pmid":"38095822","source_url":"https://pubmed.ncbi.nlm.nih.gov/38095822/","study_design":null,"title":"Lecanemab: More Questions Than Answers!","title_match":false,"year":2024},{"alzhub_score":48,"alzhub_url":"https://alzhub.org/study/review-of-donanemab-and-lecanemab-in-mild-dementia-stage-of-alzheimer-41966037","doi":"10.4140/tcp.n.2026.98","journal":"The Senior care pharmacist","n_participants":null,"pmid":"41966037","source_url":"https://pubmed.ncbi.nlm.nih.gov/41966037/","study_design":null,"title":"Review of Donanemab and Lecanemab in Mild Dementia Stage of Alzheimer's Disease: Progress and Challenges","title_match":false,"year":2026},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/diagnosis-pathomechanisms-and-therapy-of-cerebral-amyloid-angiopathy-40281535","doi":"10.1186/s42466-025-00382-3","journal":"Neurological research and practice","n_participants":null,"pmid":"40281535","source_url":"https://pubmed.ncbi.nlm.nih.gov/40281535/","study_design":null,"title":"Diagnosis, pathomechanisms and therapy of cerebral amyloid angiopathy-related inflammation (CAA-ri)","title_match":false,"year":2025},{"alzhub_score":69,"alzhub_url":"https://alzhub.org/study/the-effect-of-modified-donanemab-titration-on-amyloid-related-imaging-40619285","doi":"10.1016/j.tjpad.2025.100266","journal":"The journal of prevention of Alzheimer's disease","n_participants":null,"pmid":"40619285","source_url":"https://pubmed.ncbi.nlm.nih.gov/40619285/","study_design":null,"title":"The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6","title_match":true,"year":2025},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/balancing-speed-and-sensitivity-echo-planar-accelerated-mri-for-aria-40820597","doi":"10.1097/rli.0000000000001232","journal":"Investigative radiology","n_participants":null,"pmid":"40820597","source_url":"https://pubmed.ncbi.nlm.nih.gov/40820597/","study_design":null,"title":"Balancing Speed and Sensitivity: Echo-Planar Accelerated MRI for ARIA-H Screening in Anti-A\u03b2 Therapeutics","title_match":true,"year":2026},{"alzhub_score":52,"alzhub_url":"https://alzhub.org/study/comparing-aria-e-severity-scales-and-effects-of-treatment-management-36474747","doi":"10.1002/dad2.12376","journal":"Alzheimer's & dementia (Amsterdam, Netherlands)","n_participants":75,"pmid":"36474747","source_url":"https://pubmed.ncbi.nlm.nih.gov/36474747/","study_design":null,"title":"Comparing ARIA-E severity scales and effects of treatment management thresholds","title_match":true,"year":2022},{"alzhub_score":83,"alzhub_url":"https://alzhub.org/study/lecanemab-for-treatment-of-individuals-with-early-alzheimer-s-disease-41689888","doi":"10.1016/j.tjpad.2026.100507","journal":"The journal of prevention of Alzheimer's disease","n_participants":1795,"pmid":"41689888","source_url":"https://pubmed.ncbi.nlm.nih.gov/41689888/","study_design":"clinical trial","title":"Lecanemab for treatment of individuals with early Alzheimer's Disease (AD) who are apolipoprotein E \u03b54 (ApoE \u03b54) non-carriers or heterozygotes","title_match":false,"year":2026},{"alzhub_score":70,"alzhub_url":"https://alzhub.org/study/real-world-application-of-lecanemab-in-early-stage-alzheimer-s-41250246","doi":"10.1186/s13195-025-01886-5","journal":"Alzheimer's research & therapy","n_participants":14,"pmid":"41250246","source_url":"https://pubmed.ncbi.nlm.nih.gov/41250246/","study_design":"cohort study","title":"Real-world application of lecanemab in early-stage alzheimer's disease: a single-center prospective cohort analysis","title_match":false,"year":2025},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/radiological-identification-and-evaluation-of-amyloid-related-imaging-39990823","doi":"10.12182/20241160201","journal":"Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition","n_participants":null,"pmid":"39990823","source_url":"https://pubmed.ncbi.nlm.nih.gov/39990823/","study_design":null,"title":"[Radiological Identification and Evaluation of Amyloid-Related Imaging Abnormalities in Alzheimer's Disease]","title_match":true,"year":2024},{"alzhub_score":70,"alzhub_url":"https://alzhub.org/study/amyloid-related-imaging-abnormalities-in-japanese-patients-with-41936348","doi":"10.1016/j.tjpad.2026.100562","journal":"The journal of prevention of Alzheimer's disease","n_participants":120,"pmid":"41936348","source_url":"https://pubmed.ncbi.nlm.nih.gov/41936348/","study_design":"longitudinal study","title":"Amyloid-related imaging abnormalities in Japanese patients with Alzheimer's disease treated with Lecanemab: A real-world study","title_match":true,"year":2026},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/altered-clearance-and-amyloid-related-imaging-abnormalities-40210382","doi":"10.1016/j.nic.2024.12.002","journal":"Neuroimaging clinics of North America","n_participants":null,"pmid":"40210382","source_url":"https://pubmed.ncbi.nlm.nih.gov/40210382/","study_design":null,"title":"Altered Clearance and Amyloid-Related Imaging Abnormalities","title_match":true,"year":2025},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/symptomatic-amyloid-related-imaging-abnormalities-in-an-apoe-4-4-33072846","doi":"10.1002/dad2.12101","journal":"Alzheimer's & dementia (Amsterdam, Netherlands)","n_participants":null,"pmid":"33072846","source_url":"https://pubmed.ncbi.nlm.nih.gov/33072846/","study_design":null,"title":"Symptomatic amyloid-related imaging abnormalities in an APOE \u03b54/\u03b54 patient treated with aducanumab","title_match":true,"year":2020},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/viewpoint-clinicians-perspectives-on-how-disease-modifying-drugs-for-37357267","doi":"10.14283/jpad.2023.72","journal":"The journal of prevention of Alzheimer's disease","n_participants":null,"pmid":"37357267","source_url":"https://pubmed.ncbi.nlm.nih.gov/37357267/","study_design":null,"title":"Viewpoint: Clinicians' Perspectives on How Disease Modifying Drugs for Alzheimer's Disease Impact Specialty Care","title_match":false,"year":2023},{"alzhub_score":66,"alzhub_url":"https://alzhub.org/study/apoe-guided-lecanemab-dosing-dissociates-aria-e-from-aria-h-the-k-42642841","doi":"10.1002/alz.71765","journal":"Alzheimer's & dementia : the journal of the Alzheimer's Association","n_participants":null,"pmid":"42642841","source_url":"https://pubmed.ncbi.nlm.nih.gov/42642841/","study_design":null,"title":"APOE-guided lecanemab dosing dissociates ARIA-E from ARIA-H: The K-ROAD study","title_match":true,"year":2026},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/antibody-therapy-in-alzheimer-s-disease-42714614","doi":"10.1007/s00391-026-02640-8","journal":"Zeitschrift fur Gerontologie und Geriatrie","n_participants":null,"pmid":"42714614","source_url":"https://pubmed.ncbi.nlm.nih.gov/42714614/","study_design":null,"title":"[Antibody therapy in Alzheimer's disease]","title_match":false,"year":2026},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/from-bench-to-bedside-cutting-edge-and-emerging-therapies-for-40993929","doi":"10.2174/0118715249388723250910140541","journal":"Central nervous system agents in medicinal chemistry","n_participants":null,"pmid":"40993929","source_url":"https://pubmed.ncbi.nlm.nih.gov/40993929/","study_design":null,"title":"From Bench to Bedside: Cutting-Edge and Emerging Therapies for Alzheimer's Disease","title_match":false,"year":2025},{"alzhub_score":48,"alzhub_url":"https://alzhub.org/study/passive-alzheimer-s-immunotherapy-a-promising-or-uncertain-option-37414156","doi":"10.1016/j.arr.2023.101996","journal":"Ageing research reviews","n_participants":null,"pmid":"37414156","source_url":"https://pubmed.ncbi.nlm.nih.gov/37414156/","study_design":null,"title":"Passive Alzheimer's immunotherapy: A promising or uncertain option?","title_match":false,"year":2023},{"alzhub_score":38,"alzhub_url":"https://alzhub.org/study/cerebral-amyloid-angiopathy-related-inflammation-biomarkers-where-are-26756457","doi":"10.3233/jad-151042","journal":"Journal of Alzheimer's disease : JAD","n_participants":null,"pmid":"26756457","source_url":"https://pubmed.ncbi.nlm.nih.gov/26756457/","study_design":null,"title":"Cerebral Amyloid Angiopathy-Related Inflammation Biomarkers: Where are we Now?","title_match":false,"year":2016},{"alzhub_score":38,"alzhub_url":"https://alzhub.org/study/inflammatory-cerebral-amyloid-angiopathy-25846442","doi":"10.11477/mf.1416200132","journal":"Brain and nerve = Shinkei kenkyu no shinpo","n_participants":null,"pmid":"25846442","source_url":"https://pubmed.ncbi.nlm.nih.gov/25846442/","study_design":null,"title":"[Inflammatory cerebral amyloid angiopathy]","title_match":false,"year":2015},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/amyloid-related-imaging-abnormality-aria-beyond-the-apoe-4-allele-40951730","doi":"10.1002/cdt3.70006","journal":"Chronic diseases and translational medicine","n_participants":null,"pmid":"40951730","source_url":"https://pubmed.ncbi.nlm.nih.gov/40951730/","study_design":null,"title":"Amyloid-Related Imaging Abnormality (ARIA) Beyond the APOE-\u03b54 Allele","title_match":true,"year":2025},{"alzhub_score":63,"alzhub_url":"https://alzhub.org/study/real-world-evidence-for-amyloid-targeted-therapies-lecanemab-and-42661728","doi":"10.1002/dad2.70404","journal":"Alzheimer's & dementia (Amsterdam, Netherlands)","n_participants":89,"pmid":"42661728","source_url":"https://pubmed.ncbi.nlm.nih.gov/42661728/","study_design":null,"title":"Real-world evidence for amyloid-targeted therapies: Lecanemab and donanemab","title_match":false,"year":2026},{"alzhub_score":52,"alzhub_url":"https://alzhub.org/study/polygenic-risk-score-predicts-pathologically-confirmed-cerebral-41383049","doi":"10.1002/alz.70958","journal":"Alzheimer's & dementia : the journal of the Alzheimer's Association","n_participants":null,"pmid":"41383049","source_url":"https://pubmed.ncbi.nlm.nih.gov/41383049/","study_design":null,"title":"Polygenic risk score predicts pathologically confirmed cerebral amyloid angiopathy","title_match":false,"year":2025},{"alzhub_score":55,"alzhub_url":"https://alzhub.org/study/chit1-and-ddah1-levels-relate-to-amyloid-related-imaging-40696469","doi":"10.1186/s13195-025-01799-3","journal":"Alzheimer's research & therapy","n_participants":156,"pmid":"40696469","source_url":"https://pubmed.ncbi.nlm.nih.gov/40696469/","study_design":null,"title":"CHIT1 and DDAH1 levels relate to amyloid-related imaging abnormalities risk profile in Alzheimer's disease patients","title_match":true,"year":2025},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/guidelines-for-pharmacotherapy-in-alzheimer-s-disease-a-primer-on-fda-38059250","doi":"10.25259/jnrp_356_2023","journal":"Journal of neurosciences in rural practice","n_participants":null,"pmid":"38059250","source_url":"https://pubmed.ncbi.nlm.nih.gov/38059250/","study_design":null,"title":"Guidelines for pharmacotherapy in Alzheimer's disease - A primer on FDA-approved drugs","title_match":false,"year":2023},{"alzhub_score":76,"alzhub_url":"https://alzhub.org/study/a-phase-3-trial-of-iv-immunoglobulin-for-alzheimer-disease-28381506","doi":"10.1212/wnl.0000000000003904","journal":"Neurology","n_participants":390,"pmid":"28381506","source_url":"https://pubmed.ncbi.nlm.nih.gov/28381506/","study_design":"clinical trial","title":"A phase 3 trial of IV immunoglobulin for Alzheimer disease","title_match":false,"year":2017},{"alzhub_score":80,"alzhub_url":"https://alzhub.org/study/investigating-partially-discordant-results-in-phase-3-studies-of-36946443","doi":"10.14283/jpad.2023.6","journal":"The journal of prevention of Alzheimer's disease","n_participants":1638,"pmid":"36946443","source_url":"https://pubmed.ncbi.nlm.nih.gov/36946443/","study_design":"post-hoc analysis","title":"Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab","title_match":false,"year":2023},{"alzhub_score":54,"alzhub_url":"https://alzhub.org/study/potential-impact-of-unblinding-on-observed-treatment-effects-in-38380503","doi":"10.1002/alz.13690","journal":"Alzheimer's & dementia : the journal of the Alzheimer's Association","n_participants":null,"pmid":"38380503","source_url":"https://pubmed.ncbi.nlm.nih.gov/38380503/","study_design":"clinical trial","title":"Potential impact of unblinding on observed treatment effects in Alzheimer's disease trials","title_match":false,"year":2024},{"alzhub_score":16,"alzhub_url":"https://alzhub.org/study/serpin-a3-is-increased-in-cerebral-amyloid-angiopathy-and-aria-4f28fca6","doi":"10.64898/2026.10.19.759840","journal":"bioRxiv","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.64898/2026.10.19.759840","study_design":null,"title":"Serpin A3 is Increased in Cerebral Amyloid Angiopathy and ARIA","title_match":true,"year":2026},{"alzhub_score":16,"alzhub_url":"https://alzhub.org/study/brain-resident-myeloid-cells-promote-rapid-leukocyte-adhesion-in-005bc584","doi":"10.64898/2026.09.07.749938","journal":"bioRxiv","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.64898/2026.09.07.749938","study_design":"longitudinal study","title":"Brain-resident myeloid cells promote rapid leukocyte adhesion in leptomeningeal vessels after anti-A\u03b2 immunotherapy","title_match":false,"year":2026},{"alzhub_score":16,"alzhub_url":"https://alzhub.org/study/mapping-post-translational-modifications-across-amyloid-deposits-in-35f2647e","doi":"10.21203/rs.3.rs-10769225/v1","journal":"Research Square","n_participants":19,"pmid":null,"source_url":"https://doi.org/10.21203/rs.3.rs-10769225/v1","study_design":null,"title":"Mapping post-translational modifications across amyloid-\u03b2 deposits in Alzheimer\u2019s disease: A neuropathologic survey with in vitro functional analysis of nitration","title_match":false,"year":2026},{"alzhub_score":16,"alzhub_url":"https://alzhub.org/study/real-world-characterization-of-amyloid-related-imaging-abnormalities-4202aa20","doi":"10.64898/2026.01.23.26344739","journal":"medRxiv","n_participants":468,"pmid":null,"source_url":"https://doi.org/10.64898/2026.01.23.26344739","study_design":"cohort study","title":"Real-World Characterization of Amyloid-Related Imaging Abnormalities (ARIA) in Lecanemab Treatment at an Academic Health System","title_match":true,"year":2026},{"alzhub_score":16,"alzhub_url":"https://alzhub.org/study/anti-amyloid-immunotherapy-drives-apoe4-specific-increases-in-glial-922ec944","doi":"10.64898/2026.06.26.734793","journal":"bioRxiv","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.64898/2026.06.26.734793","study_design":null,"title":"Anti-amyloid immunotherapy drives APOE4 specific increases in glial reactivity, perivascular immune activation, and ARIA-like events","title_match":true,"year":2026},{"alzhub_score":16,"alzhub_url":"https://alzhub.org/study/mch-guard-multimodal-machine-learning-framework-for-risk-87340723","doi":"10.64898/2026.06.18.26355972","journal":"medRxiv","n_participants":813,"pmid":null,"source_url":"https://doi.org/10.64898/2026.06.18.26355972","study_design":"longitudinal study","title":"MCH-Guard: Multimodal Machine Learning Framework for Risk Stratification of Cerebral Microhemorrhage Risk in the Alzheimer\u2019s Disease Neuroimaging Initiative","title_match":false,"year":2026},{"alzhub_score":16,"alzhub_url":"https://alzhub.org/study/dynamic-imaging-markers-of-aria-h-risk-in-the-a4-study-a-person-16617b5e","doi":"10.64898/2026.05.30.26354521","journal":"medRxiv","n_participants":1069,"pmid":null,"source_url":"https://doi.org/10.64898/2026.05.30.26354521","study_design":null,"title":"Dynamic Imaging Markers of ARIA-H Risk in the A4 Study: A Person-Interval Analysis of Current Lesion Burden and Recent Microhaemorrhage Activity","title_match":true,"year":2026},{"alzhub_score":16,"alzhub_url":"https://alzhub.org/study/automated-quantification-of-cerebral-microbleeds-for-aria-h-23d6501e","doi":"10.64898/2026.05.19.26353364","journal":"medRxiv","n_participants":264,"pmid":null,"source_url":"https://doi.org/10.64898/2026.05.19.26353364","study_design":null,"title":"Automated quantification of cerebral microbleeds for ARIA-H monitoring in Aging and Alzheimer\u2019s Disease: A multicenter deep learning validation","title_match":true,"year":2026},{"alzhub_score":16,"alzhub_url":"https://alzhub.org/study/intravenous-anti-a-immunotherapy-acutely-increases-cerebral-amyloid-5846ffcd","doi":"10.64898/2026.02.09.704876","journal":"bioRxiv","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.64898/2026.02.09.704876","study_design":null,"title":"Intravenous anti-A\u03b2 immunotherapy acutely increases cerebral amyloid angiopathy and vascular damages in APOE4 mice","title_match":false,"year":2026},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/early-binding-of-anti-amyloid-antibodies-to-caa-drives-complement-7ec97b6f","doi":"10.64898/2026.03.04.709591","journal":"Molecular neurodegeneration","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.64898/2026.03.04.709591","study_design":null,"title":"Early Binding of Anti-Amyloid Antibodies to CAA Drives Complement Activation, Inflammation and ARIA in Mice","title_match":true,"year":2026},{"alzhub_score":16,"alzhub_url":"https://alzhub.org/study/a-simulation-based-discrete-choice-experiment-framework-for-0a617270","doi":"10.21203/rs.3.rs-9404461/v1","journal":"Research Square","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.21203/rs.3.rs-9404461/v1","study_design":null,"title":"A Simulation-Based Discrete Choice Experiment Framework for Alzheimer\u2019s Disease-Modifying Therapy Implementation: Methodology and Interactive Decision Support Tool","title_match":false,"year":2026},{"alzhub_score":16,"alzhub_url":"https://alzhub.org/study/a-biophysical-framework-for-neurodegeneration-prioritizing-protein-7b94959b","doi":"10.20944/preprints202512.2722.v1","journal":"Preprints.org","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.20944/preprints202512.2722.v1","study_design":null,"title":"A Biophysical Framework for Neurodegeneration: Prioritizing Protein Homeostasis Over Aggregate Toxicity","title_match":false,"year":2025},{"alzhub_score":16,"alzhub_url":"https://alzhub.org/study/scfv-h3d6-prevents-bapineuzumab-induced-hemorrhagic-events-in-the-343d96ed","doi":"10.20944/preprints202511.0180.v1","journal":"Preprints.org","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.20944/preprints202511.0180.v1","study_design":null,"title":"ScFv-h3D6 Prevents Bapineuzumab-Induced Hemorrhagic Events in the APP23 Mouse Model of Alzheimer\u2019s Disease","title_match":false,"year":2025},{"alzhub_score":16,"alzhub_url":"https://alzhub.org/study/real-world-experience-with-lecanemab-therapy-for-alzheimers-disease-b62fc105","doi":"10.1101/2025.09.30.25337002","journal":"medRxiv","n_participants":70,"pmid":null,"source_url":"https://doi.org/10.1101/2025.09.30.25337002","study_design":null,"title":"Real-world experience with lecanemab therapy for Alzheimer\u2019s disease in the Intermountain West","title_match":false,"year":2025},{"alzhub_score":16,"alzhub_url":"https://alzhub.org/study/xpro1595-a-selective-soluble-tnf-neutralizer-in-early-alzheimers-377d6a5b","doi":"10.1101/2025.09.24.25336496","journal":"medRxiv","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.1101/2025.09.24.25336496","study_design":"clinical trial","title":"XPro1595, a Selective Soluble TNF Neutralizer, in Early Alzheimer\u2019s Disease with Inflammation (ADi): Results from the Phase 2 MINDFuL Trial","title_match":false,"year":2025},{"alzhub_score":40,"alzhub_url":"https://alzhub.org/study/data-driven-modeling-of-amyloid-beta-targeted-antibodies-for-32628a51","doi":"10.21203/rs.3.rs-6316455/v1","journal":"NPJ systems biology and applications","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.21203/rs.3.rs-6316455/v1","study_design":null,"title":"Data-Driven Modeling of Amyloid-beta Targeted Antibodies for Alzheimer\u2019s Disease","title_match":false,"year":2025},{"alzhub_score":47,"alzhub_url":"https://alzhub.org/study/inflammation-in-alzheimers-disease-insights-from-immunotherapy-23983027","doi":"10.1093/brain/awt231","journal":"Brain","n_participants":39,"pmid":"23983027","source_url":"https://pubmed.ncbi.nlm.nih.gov/23983027/","study_design":null,"title":"Inflammation in Alzheimer\u2019s disease: insights from immunotherapy","title_match":false,"year":2013},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/o40405-aducanumab-biib037-an-antiamyloid-beta-monoclonal-antibody-in-204cb97e","doi":"10.1016/j.jalz.2015.07.367","journal":"Alzheimer s & Dementia","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.1016/j.jalz.2015.07.367","study_design":null,"title":"O4\u201004\u201005: Aducanumab (BIIB037), an anti\u2010amyloid beta monoclonal antibody, in patients with prodromal or mild Alzheimer's disease: Interim results of a randomized, double\u2010blind, placebo\u2010controlled, phase 1b study","title_match":false,"year":2015},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/anti-amyloid-therapies-for-alzheimers-disease-progress-pitfalls-and-41096797","doi":"10.3390/ijms26199529","journal":"International Journal of Molecular Sciences","n_participants":null,"pmid":"41096797","source_url":"https://pubmed.ncbi.nlm.nih.gov/41096797/","study_design":null,"title":"Anti-Amyloid Therapies for Alzheimer\u2019s Disease: Progress, Pitfalls, and the Path Ahead","title_match":false,"year":2025},{"alzhub_score":55,"alzhub_url":"https://alzhub.org/study/o41106-a-randomized-doubleblind-placebocontrolled-phase-2-study-to-a7c335d7","doi":"10.1016/j.jalz.2014.04.450","journal":"Alzheimer s & Dementia","n_participants":433,"pmid":null,"source_url":"https://doi.org/10.1016/j.jalz.2014.04.450","study_design":"clinical trial","title":"O4\u201011\u201006: A RANDOMIZED, DOUBLE\u2010BLIND, PLACEBO\u2010CONTROLLED PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CRENEZUMAB IN PATIENTS WITH MILD TO MODERATE ALZHEIMER'S DISEASE","title_match":false,"year":2014},{"alzhub_score":62,"alzhub_url":"https://alzhub.org/study/trailblazer-alz-4-topline-study-results-directly-comparing-donanemab-7521651f","doi":"10.1192/bjo.2023.227","journal":"BJPsych Open","n_participants":148,"pmid":null,"source_url":"https://doi.org/10.1192/bjo.2023.227","study_design":"clinical trial","title":"TRAILBLAZER-ALZ 4: Topline Study Results Directly Comparing Donanemab to Aducanumab on Amyloid Lowering in Early, Symptomatic Alzheimer's Disease","title_match":false,"year":2023},{"alzhub_score":55,"alzhub_url":"https://alzhub.org/study/dt0103-efficacy-and-safety-of-gantenerumab-in-prodromal-alzheimer-s-f0473682","doi":"10.1016/j.jalz.2015.08.153","journal":"Alzheimer s & Dementia","n_participants":312,"pmid":null,"source_url":"https://doi.org/10.1016/j.jalz.2015.08.153","study_design":"clinical trial","title":"DT\u201001\u201003: Efficacy and safety of gantenerumab in prodromal Alzheimer's disease: Results from scarlet road\u2014a global, multicenter trial","title_match":false,"year":2015},{"alzhub_score":34,"alzhub_url":"https://alzhub.org/study/p4285-sar228810-an-antiprotofibrillar-betaamyloid-antibody-designed-c5f3311d","doi":"10.1016/j.jalz.2013.05.1678","journal":"Alzheimer s & Dementia","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.1016/j.jalz.2013.05.1678","study_design":null,"title":"P4\u2013285: SAR228810: An antiprotofibrillar beta\u2010amyloid antibody designed to reduce risk of amyloid\u2010related imaging abnormalities (ARIA)","title_match":true,"year":2013},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/assessing-preparedness-for-alzheimer-diseasemodifying-therapies-in-36934371","doi":"10.5694/mja2.51880","journal":"The Medical Journal of Australia","n_participants":null,"pmid":"36934371","source_url":"https://pubmed.ncbi.nlm.nih.gov/36934371/","study_design":"clinical trial","title":"Assessing preparedness for Alzheimer disease\u2010modifying therapies in Australasian health care systems","title_match":false,"year":2023},{"alzhub_score":52,"alzhub_url":"https://alzhub.org/study/p2003-clinical-trial-design-of-cread-a-randomized-doubleblind-916a25c5","doi":"10.1016/j.jalz.2016.06.1207","journal":"Alzheimer s & Dementia","n_participants":500,"pmid":null,"source_url":"https://doi.org/10.1016/j.jalz.2016.06.1207","study_design":"clinical trial","title":"P2\u2010003: Clinical Trial Design of Cread: A Randomized, Double\u2010Blind, Placebo\u2010Controlled, Parallel\u2010Group Phase 3 Study to Evaluate Crenezumab Treatment in Patients with Prodromal\u2010To\u2010Mild Alzheimer\u2019s Disease","title_match":false,"year":2016},{"alzhub_score":50,"alzhub_url":"https://alzhub.org/study/aducanumab-36-month-data-from-prime-a-randomized-double-blind-placebo-12a02583","doi":"10.1212/wnl.90.15_supplement.s2.004","journal":"Neurology","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.1212/wnl.90.15_supplement.s2.004","study_design":"clinical trial","title":"Aducanumab 36-month data from PRIME: a randomized, double-blind, placebo-controlled Phase 1b study in patients with prodromal or mild Alzheimer\u2019s disease (S2.004)","title_match":false,"year":2018},{"alzhub_score":48,"alzhub_url":"https://alzhub.org/study/comparative-methods-for-quantifying-plasma-biomarkers-in-alzheimer-s-37908054","doi":"10.1002/alz.13510","journal":"Alzheimer's & dementia : the journal of the Alzheimer's Association","n_participants":null,"pmid":"37908054","source_url":"https://pubmed.ncbi.nlm.nih.gov/37908054/","study_design":null,"title":"Comparative methods for quantifying plasma biomarkers in Alzheimer's disease: Implications for the next frontier in cerebral amyloid angiopathy diagnostics","title_match":false,"year":2024},{"alzhub_score":80,"alzhub_url":"https://alzhub.org/study/bapineuzumab-for-mild-to-moderate-alzheimer-s-disease-in-two-global-27176461","doi":"10.1186/s13195-016-0189-7","journal":"Alzheimer's research & therapy","n_participants":329,"pmid":"27176461","source_url":"https://pubmed.ncbi.nlm.nih.gov/27176461/","study_design":"clinical trial","title":"Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials","title_match":false,"year":2016}]}